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ABSTRACT 
OBJECTIVE: To study the effects of perioperative glycemic control and their 
impact on postoperative infections in various general surgical procedures in 
patients with diabetes mellitus. 
BACKGROUND: Patients with diabetes are more likely to undergo various 
surgical procedures than non-diabetics.  Perioperative glycaemic control in 
diabetics is challenging and leads to lesser postoperative infectious 
complications. This study helps to establish the significance of strict glycaemic 
control in these patients. 
METHODS: A prospective study of 50 diabetic patients undergoing various 
surgical procedures was done for the association of perioperative glycaemic 
control and the incidence of postoperative infections for a 30-day period during 
the period, from 1.1.2014 to 30.06.2014 in Thanjavur Medical College.  The 
stastical significance and the overall incidence of postoperative infections were 
analysed with the amount of glycaemic control achieved. 
RESULTS: Of the 50 patients, 28 were males and 22 females. The mean age of 
the study is 54 years. 35 patients of elective surgery and 15 patients of 
emergency surgery were included.  Mean plasma glucose concentration in the 
perioperative period calculated and patients were divided into four quartiles (I-
120-180 mg/dl; II-181 to 220 mg/dl; III-221 to 260 mg/dl; IV-261 to 350 mg/dl) 
accordingly.  The incidence of SSIs in each quartile (I-IV) was 16.7%, 54.5%, 
66.7% & 100% respectively. 13.3%, 18.2% 33.3% & 66.7% incidence of 
pneumonia and 6.7%, 9.1%, 16.7% & 33.3% incidence of UTI occurred in 
quartile I to quartile IV respectively.  Similarly the rate of occurrence of sepsis 
is 18.2% in II, 33.3% in III and 66.7% in IV quartile with no sepsis in I quartile 
patients.  The overall incidence of postoperative infectious complications in 
each quartile from I to IV is 36.7%, 72.7%, 83.3% and 100% respectively.  SSI 
accounted for the most common and sepsis for the least common complication 
in these patients.  Insulin therapy proved to be a better way to achieve 
glycaemic control in these patients. The optimal glycaemic range desired is 
between 120 to 180 mg/dl.  
CONCLUSION: Good perioperative glycaemic control is associated with a 
decrease in postoperative infectious complications in diabetic patients 
undergoing various surgical procedures. 
  
 
INTRODUCTION 
 
The primary goal of a surgeon is to provide the patient a quick, painless 
and safe recovery from surgery as possible.  Infections following surgical 
procedures result in pain, poor wound healing, need for additional treatment 
including antibiotics, extended hospital stays, and increased health care 
expenditures. 
 Postoperative infections may cause several problems, which include 
failure of the surgical procedure, other surgical complications, sepsis, organ 
failure, and even death.  
Diabetes mellitus is an increasing challenge to the surgeons, since these 
patients are at greater risk of developing postoperative infections when 
compared to the non-diabetic patients.Alarmingly, diabetes mellitus is being 
diagnosed more often in younger patients.  Strict glycaemic control in the 
postoperative period has significantly reduced the morbidity in these patients 
and has increased overall survival rates. 
 
 
  
 
 
Identifying the factors that play an increased role in the patient with 
diabetes mellitus can help to alleviate  postoperative infection through 
education, controlling hyperglycaemia, administering appropriate antibiotics 
whenever needed, and ensuring that the patient is in adequate nutritional status. 
This prospective study on perioperative glycaemic control and 
postoperative infections will give us better understanding about the importance 
of glycaemic control in diabetes mellitus and helps lessen the burden of 
postoperative morbidity in these patients.  
 
 
 
 
 
 
 
 
  
 
 
 
 
AIMS AND OBJECTIVES 
• To study about the preoperative glycaemic control and postoperative 
infections. 
• To study about the postoperative glycaemic status and postoperative 
infections. 
• To study the range of the blood sugar to be maintained. 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
 
SELECTION OF STUDY SUBJECTS: 
 All patients with diabetes mellitus who satisfy the inclusion criteria are 
studied with perioperative blood sugar values and postoperative wound 
infections, urinary tract infections, lower respiratory tract infections and sepsis. 
 
INCLUSION CRITERIA: 
• Patients presenting with diabetes mellitus undergoing general surgical 
procedures. 
 
EXCLUSION CRITERIA: 
• Patients without diabetes mellitus. 
• Patients with major comorbid illness. 
• Patients presenting with postoperative infections within 36 hours of 
surgery. 
• Patients who were not given consent for surgery. 
  
 
INVESTIGATIONS DONE: 
• Blood sugar values 
• Hb A1C 
 
DATA COLLECTION METHODS: 
• Clinical 
• Blood reports 
• Culture & sensitivity reports 
 
STUDY DESIGN : Prospective study 
STUDY PERIOD : 1.1.2014 – 30.06.2014 
STUDY PLACE : THANJAVUR MEDICAL COLLEGE AND HOSPITAL 
 
 
 
 
  
 
REVIEW OF LITERATURE 
 Diabetes mellitus is one of the diseases of the modern era and it 
approximately affects 230 million people worldwide.The term is derived from 
the Greek words dia (=through),bainein (=to go) and diabetes literally means 
pass through.The disease causes loss of weight as if the body mass is passed 
through the urine. The Greek word, mellitus, means sweet, as it is known to 
early workers, that the urine of the patient contains sugar. Diabetes mellitus is a 
disease known from very ancient times. Charaka in his treatise (circa 400BC) 
gives a very elaborate clinical description of madhumeha(= sweet urine). He 
had the vision that carbohydrate and fat metabolisms are altered in this disease. 
In Western literature,Thomas Willis in 1670 noticed the sweet taste of diabetic 
urine. In 1838, Bouchardt and Peligot proved that the sugarof diabetic urine is 
the same as that present in grape sugar.Diabetes mellitus is a metabolic disease 
due to absolute or relative insulin deficiency. Diabetes mellitus is a common 
clinical condition. It is a major cause for morbidity and mortality. Insulin 
deficiency leads to increased blood glucose level.In spite of this high blood 
glucose, the entry of glucose into the cell is inefficient. Hence, all cells are 
starved of glucose. 
 
  
There is an expanding incidence and  prevalence of diabetes mellitus. 
About 10% of the total population, and about 1/5th of persons above the age of 
50, suffer from this disease.About 50% of people suffering from diabetes 
mellitus are ignorant of their condition.  Approximately 25% of patients with 
diabetes who undergo surgery are undiagnosed on admission to hospital.  
Patients with diabetes have a greater risk of certain diseases like cardiovascular 
disease, etc.  Patients with diabetes have a greater perioperative risk for 
developing infections.  This is more likely because of their disease to need 
surgery and those who undergo surgery are likely to be less well-controlled and 
to have complications from their diabetes according to their glycaemic control. 
 
 Diabetic patients with tight long-term glucose control as measured by the 
percentage of haemoglobin A1c (HbA1c) has reduced incidence and severity 
of most of the chronic complications associated with diabetes, such as 
nephropathy, neuropathy, andretinopathy.It has not been well established 
whether long term glycaemic control also helps mitigate acute infectious 
complications in the perioperative period.  Therefore this study has been 
chosen to determine whether good perioperative glycaemic control is 
associated with decreased incidence of postoperative infections in patients with 
type 2 diabetes undergoing a various surgical procedures. 
 
  
 Hyperglycemia has the potential to affect multiple pathways of the 
immune system.It may cause decreased phagocytic and chemotactic functions 
in neutrophils and monocytes, increased rates of apoptosis of the neutrophils 
and decreased ability of the monocytes to present antigen.  Hyperglycemia 
primarily affects the cellular immune system.  It stimulates inflammatory 
cytokines and affects the microcirculation, thereby increasing the risk for 
infection and preventing the phenomena of normal wound healing.  
Hyperglycemia is a common occurrence in patients undergoing surgery, and 
undiagnosed insulin resistance identified on the day of surgery is increasingly 
common.  Perioperative hyperglycemia has been associated with postoperative 
complications in vascular surgery, mastectomies, neurosurgery, spine surgery, 
transplant surgery, colorectal surgery, hepato-biliary-pancreatic surgery, 
cholecystectomy, etc.  There are evidences that suggest that hyperglycemia is 
modifiable, independent predictor and possibly a casual factor of adverse 
outcomes in diabetic patients. 
 
 Intensive diabetic therapy with improved blood glucose control has been 
shown to delay the long term detrimental effects of microvascular 
complications and to prevent impairment of the white blood cell’s ability to 
phagocytose and effectively kill bacteria.  Several studies had showed a 
significant positive correlation between the mean plasma glucose levels and 
the frequency of acute infections.  The diminution of intracellular bactericidal 
  
activity of leukocytes to both Staphylococcus aureus and Escherichia coli was 
shown to have a direct relation to glucose control.  Similarly short term 
hyperglycaemia is also associated with detrimental effect on the ability of 
immunoglobulin G to fix complement.  Further, extracellular glycosylation of 
proteins in diabetics has been shown to impair wound healing and is associated 
with increased collagenase activity and decreased wound collagen content. 
 
DIABETES MELLITUS 
Diabetes mellitus is a common disease in man. A predisposition to the 
disease is probably inherited as an autosomal recessive trait. About 25 per cent 
of relatives of diabetics show abnormal glucose tolerance curves as compared to 
1 per cent in the general population. 
 
Definition: 
A  chronic  disease primarily due to a disorder of carbohydrate 
metabolism, cause of which is deficiency or diminished effectiveness of insulin, 
resulting in hyperglycaemia and glycosuria. Secondary changes may occur in 
the metabolism of proteins, fats, water and electrolytes and in tissues/organs 
sometimes with grave consequences. 
 
 
 
  
STAGES OF DIABETES MELLITUS 
Since “overt” diabetes is not usually seen till after the age of 40, there 
must be a stage of Pre-diabetes which dates from the time of 
conception.American DiabetesAssociation has divided into four stages. The 
four stages and findings are shown below in tabular form in the box. 
 
Stages GTT FBS 
Plasma 
insulin 
Symptoms Angiopathies 
Pre-diabetes Normal Normal Normal None + 
Suspected 
diabetes 
Abnormal 
May be 
normal 
Normal 
Symptoms 
after stress 
+ 
Chemical/Latent 
Diabetes 
Abnormal 
Normal 
or raised 
Normal 
or raised 
Unusual ++ 
Overt Diabetes Abnormal Raised 
Normal 
or low 
Usual +++ to ++++ 
 
 
CLINICAL TYPES AND CAUSES 
These are two main groups: 
(a) Primary (Idiopathic):  It constitutes the major group. Exact cause is 
not known; metabolic defect is insufficient insulin which may be 
absolute or relative. 
  
 
(b) Secondary:  Constitutes minor group where it can be secondary to 
some disease process. 
 
(a) Primary (Idiopathic) 
Two clinical types: 
• “Juvenile”-onset diabetes: Now called as Type-I-(Insulin 
dependent)—IDDM. 
• “Maturity” onset diabetes: Type-II NIDDM— (Non-Insulin 
Dependent). 
 
Other Factors 
1. Heredity: In both types, familial tendency noted.Genetic factors are 
more important in those who develop after 40. In younger, “Juvenile” type, 
susceptibility is associated with particular HLA phenotype. Risk is two to three 
times more in those who are HLA phenotype B8 or BW15. 
 
2. Autoimmunity: Insulin-dependent juvenile type maybe an autoimmune 
disorder and has been found to co-exist with other autoimmune disorders. 
Evidences in favour of autoimmunity: 
• Lymphocytic and plasma cells infiltrations in pancreas 
• Detection of auto antibodies by immunofluorescence. 
  
 
3. Infections: Certain viral infections may precipitate Juvenile type. 
Experimentally it has been shown that certain viruses can induce diabetes. 
Incidence is high after mumps. Antibodies to coxsackie B4 virus have 
been found in young Juvenile type. 
 
4. Obesity: Majority of middle aged maturity-onset diabetics are obese, 
“stress” like pregnancy may precipitate. 
 
5. Diet: Over-eating and under activity are also predisposing factors in 
elderly middle aged maturity onset diabetes. 
 
6. Insulin antagonism: In “maturity onset” diabetes, the deficiency of 
insulin is relative and glucose induced insulin secretion may be greater and 
more prolonged than normal. This relative deficiency may be due to insulin 
antagonism, exact cause for the same is not known but various factors have 
been incriminated from time to time. They are: 
• Synalbumin of Vallence-Owen in plasma,dialyzable, thermostable 
substance. 
• β1-lipoprotein factor: Another similar factor foundin β1-lipoprotein 
fraction of plasma in diabetics. 
 
  
• Insulin “antibodies”. 
• Secretion of abnormal and less active insulin or‘altered’ insulin. 
• A “tissue barrier” to the transport of insulin to the cells, probably 
“receptor” deficiency. 
• Lack of cellular response to insulin. 
 
(b)Secondary:  
This forms a minor group. Diabetes issecondary to some other diseases. 
1. Pancreatic diabetes: 
• Pancreatitis 
• Haemochromatosis 
• Malignancy of Pancreas. 
 
2. Abnormal concentrations of antagonistic hormones: 
• Hyperthyroidism 
• Hypercorticism: like Cushing’s disease andSyndrome 
• Hyperpituitarism: Like acromegaly 
• Increased glucagon activity. 
 
3. Iatrogenic: In genetically susceptibles, may be precipitated by therapy 
like corticosteroids, thiazidediuretics. 
 
  
Recent Advances In Diabetes Mellitus 
1. Immune “markers” in type IDM (IDDM): The recent area of interest is 
the role of “glutamic acid decarboxylase” (GAD) as antigen of potential 
significance.Recently anti-GAD antibodies have been deomonstrated in most 
newly diagnosed IDDM (Type I) patients and in predictable first degree 
relatives.In adults presence of GAD antibody is a “marker” for slow onset Type 
I DM (IDDM) and helps to differentiate IDDM with age of onset > greater than 
35 years and TypeII (NIDDM). The term “Latent Autoimmune DM” inadults or 
“LADA” is now being used for such patients. 
 
2. Genes of  DM discovered: As seen above, some people may be 
genetically susceptible to Non-insulin dependent (NIDDM) or adult onset 
diabetes. Recently researchers have discovered 2 (two) genes, called MODY 1 
and MODY 3, that appear to contribute to the 2 to 5 per cent of Diabetes cases 
that are clearly inheritable.MODY 3 gene, located on chromosome 12, produces 
hepatocyte nuclear factor-1α (HNF-1α), a protein found in the Liver and in the 
β-cells of the pancreas. Pancreaticβ-cells produce insulin, the hormone that 
regulates bloodsugar levels.“MODY 1 gene”, located on chromosome 20, 
makes hepatocyte nuclear factor 4α (HNF 4α), a cell receptor that plays a role in 
HNF-1α production.The biological effects of mutant forms of HNF-1α and 
HNF-4α are still not known clearly. 
 
  
Presentation 
The disease has a varied presentation. 
• Glycosuria may be detected during routine examination of urine 
like annual check-up or when doing routine examination due to some 
other diseases. There may not be any symptoms/signs. 
• Some may present with all classical symptoms like thirst, 
polydypsia, Polyuria, Polyphagia, loss of weight etc. (“Overt” diabetics). 
• Some women present during pregnancy (stress) 
 
• A few specially Type-1 cases may present as fulminant 
ketoacidosis and a few with complications. 
 
Clinical Features & Biochemical Correlation: 
• Large amounts of glucose may be excreted in urine(may be 90 to 100 
G/day in some cases). Loss of solute produces osmotic diuresis thus large 
volume of urine(polyuria). 
• Loss of fluid leads to thirst and polydypsia. 
• Polyphagia: Eats more frequently. More fond of sweets. The above 
symptoms may persist for many months in maturity-onset diabetes. In juvenile 
onset type-1, further symptoms develop if treatment is not started. 
 
  
• Tissues including muscles received liberal supply of glucose but cannot 
use glucose due to absolute or relative deficiency of insulin/ or transport defect 
to cells. This causes weakness and tiredness. 
 
• As glucose cannot be used for fuel, fat is mobilised leading to increase 
FFA- in blood and liver. 
 
• Increased acetyl-CoA is diverted for cholesterol synthesis—
Hypercholesterolaemia and atherosclerosis. Xanthomas may develop. Increased 
ketone bodies leads to acidosis, which leads to hyperventilation (“air-hunger”). 
 
• If ketosis is severe, acetone will be breathed out, giving characteristic 
“fruity” smell in breath (due to acetone). 
 
• Along with above, there may be excessive breakdown of tissue proteins. 
Deaminated amino acids are catabolised to provide energy, which accounts for 
loss of weight. 
 
• Due to ketosis, develops anorexia, nausea, and vomiting.Continued loss 
of water and electrolytes increases dehydration. 
 
  
• Ketoacidosis produces increasing drowsiness, leading to diabetic coma 
in untreated cases. 
 
Metabolic Changes In Diabetes Mellitus 
 
1. Hyperglycaemia occurs as a result of: 
• Decreased and impaired transport and uptake ofglucose into muscles 
and adipose tissues. 
 
• Repression of key glycolytic enzymes like Glucokinase, phospho 
fructokinase and pyruvate kinase takes place. 
 
• Derepression of key gluconeogenic enzymes like Pyruvate carboxylase, 
phosphoenol pyruvate carboxykinase, fructose biphosphatase andglucose-             
6-phosphatase occur, promoting gluconeogenesis in Liver. This further 
contributes to hyperglycaemia. 
 
• Elevated amino acid level in the blood particularly alanine provides fuel 
for gluconeogenesis in Liver. 
 
 
 
  
 
2. Amino Acids Level 
• Transport and uptake of amino acids in peripheral tissues is also 
depressed causing an elevated circulating level of amino acids, particularly 
alanine. Gluco corticoid activity predominates having catabolic action on 
peripheral tissue proteins, releasing more amino acids in blood. 
 
   • Amino acids breakdown in Liver results in increased production of urea N ↑. 
 
3. Protein synthesis: Protein synthesis is decreased in all tissues due to: 
• Decreased production of ATP↓ 
• Absolute or relative deficiency of Insulin. 
 
4. Fat Metabolism 
• Decrease extra mitochondrial de Novo synthesis of FA and also TG 
synthesis due to decrease in acetyl-CoA from carbohydrates, ATP, NADPH and 
α-glycero-(p) in all tissues. 
• Stored lipids are hydrolysed by increased Lipolysis liberating free fatty 
acids (FFA)↑.Increased FFA interferes at several steps of carbohydrate 
phosphorylation in muscles, further contributing to hyperglycaemia. Effects of 
Increased FFA Level 
 
  
 
• FFA reaching the Liver in high concentration inhibits further FA 
synthesis by a feedback inhibition at the acetyl-CoA carboxylase step. 
 
• Fats are mobilised for energy; increased fatty acid oxidation increases 
acetyl-CoA level, which in turn activates Pyruvate carboxylase, stimulating the 
gluconeogenic pathway required for conversion of amino acids C-skeletons to 
glucose. 
 
• FA also stimulates gluconeogenesis by entering TCA cycle and 
increasing production of citrates↑. Citrate in turn inhibits glycolysis at 
phosphofructokinase level. 
 
• Eventually FA inhibits TCA cycle at the level of citrate synthase and 
possibly pyruvate dehydrogenase complex and Isocitrate dehydrogenase level. 
 
• Acetyl-CoA which no longer can be channelized  to TCA cycle or be 
used for FA synthesis are diverted to: 
• Cholesterol synthesis 
• Ketone bodies formation. Excessive production of ketone bodies 
increases the concentration of ketone bodies in blood (ketonaemia) and 
excretion of ketone bodies in urine (ketonuria) and leads to acidosis. 
  
 
5. Effect on glycogen synthesis: Glycogen synthesis is depressed as a result of: 
• Decreased glycogen synthase activity due to deficiency of insulin. 
• By activation of phosphorylase producing glycogenolysis through the 
action of epinephrine and/or glucagon (antagonistic) hormones. 
• By increased ADP: ATP ratio. 
 
The insulin-deficient person is in a state of hormonal imbalance favouring 
the action (Preponderance) of glucocorticoids, growth hormone and glucagon, 
all of which add to the stimulation of gluconeogenesis, lipolysis and decreased 
intracellular metabolism. 
 
 
 
. 
  
 
6. Other Effects of Hyperglycaemia 
(a) Glycosylation of Hb and formation of glycosylated Hb (HbA1C):  
Glycosylated haemoglobins particularly HbA1C rises in prolonged and 
uncontrolled diabetes 3 to 4 times than the normal level. 
 
(b) Non-enzymatic glycosylation of other proteins as plasma albumin, 
collagenous tissues and the lens protein α-crystallin:  Such glycosylations of 
collagenous tissues bring about thickening and morphologicalchanges of vessel 
walls and also glomerular basement membrane thickening. Glycosylation of 
lens protein may also account for diabetic cataract. Diabetic cataract 
biochemically may be due to: 
• Glycosylation of Lens Proteins, i.e. α-crystallin. 
• Accumulation of ‘sorbitol’ which produces osmotic damage. 
 
7. Sorbitol (polyol) pathway and phosphoinositide metabolism: Over the 
past few years, quest to discrete pathogenetic mechanisms for the long-term 
complications of Diabetes has gradually focussed on three promising targets for 
specific therapeutic intervention: 
• Non-enzymatic glycosylation of Proteins  
• Altered ‘microvascular’ haemodynamics, and 
• Abnormal sorbitol (polyol)—inositol metabolism. 
  
 
1. Striking structural similarity between glucose and Myoinositol (MI) results in 
competition for high affinity myoinositol transporters which explains the 
selective tissue depletion of myoinositol that accompanies hyperglycaemia. 
Glucose interferes with“carrier-mediated” myoinositol transport in various 
tissues specially intestine, renal brush border membranes, peripheral nerves and 
renal glomerulus. Thus hyperglycaemia may selectively deplete myoinositol 
from tissues. 
 
2. When tissues that exhibit diabetic complications are exposed to 
hyperglycaemia, sorbitol (Polyol—alcohol), accumulates because of an increase 
in the conversion of intracellular glucose to sorbitol by the high Km, i.e. low 
affinity enzyme aldose reductase and myoinositol level falls. 
 
3. High milli-molar levels of sorbitol that accumulate in Lens of eye cause 
osmotic damage, which has been linked to the development of Diabetic cataract. 
 
4. Inositol-1,4,5-triphosphate is thought to mobilise intracellular 
Ca++sequestered in the endoplasmic reticulum. Due to decrease in Inositol 
Polyphosphaterelease, Ca++ mobilisation is decreased. 
 
  
5. Due to decreased availability of Diacylglycerol and lower Ca++ mobilisation 
proteinkinase C activity is decreased, resulting in lowered Na+-K+ ATPase 
activity, resulting to Na accumulation in tissues. 
 
Clinical Aspect: Several inhibitors like Sorbinil, an aldosereductase inhibitor, 
the first enzyme in the metabolic cascade shown above can prevent or reverse 
early diabetic complications in laboratory animals and are being extensively 
undergoing clinical trials in patients with Diabetes mellitus. 
 
Complications Of Diabetes 
I. Immediate: Diabetic ketoacidosis and coma is one ofthe most important and 
dreaded complication specially in Type-I. 
 
II. Late complications: Other complications are late to appear and are due to 
changes in blood vessels. These are two types: 
• Involvement of large vessels 
• Involvement of small vessels. 
 
(a) Large vessels involvement: Atherosclerosis and its effects: 
• Involvement of coronary vessels can produce myocardial infarction. 
• Involvement of cerebral vessels can produce“stroke”. 
 
  
 
(b) Small vessels changes involve: 
• Thickening of basement membrane 
• Microvascular changes. 
 
1. Diabetic retinopathy (70%): Tiny haemorrhages,punctate or flame-shaped, 
exudates. Haemorrhage in vitreous humour can cause sudden blindness. 
 
2. Diabetic cataract: Is due to: 
• Non-enzymatic glycosylation of lens protein,α-crystallin; 
• Osmotic damage to lens protein due to accumulation of sorbitol. 
 
3. Diabetic nephropathy (50% cases): Characterised by 
(a) Proteinuria 
(b) Hypertension 
(c) Oedema.  
The triad is called as Kimmelsteil-Wilson syndrome.Microscopic lesions 
are called as ‘Kimmelsteil-Wilsonlesions/disease’. Lesions are often present 
when syndrome is not developed. Sometimes kidney lesions may be shown as: 
• Papillary necrosis: A dangerous complication. 
• Pyelonephritis: When secondary infections occur. 
 
  
 
4. Peripheral neuritis (neuropathy): Manifestated by loss of sensation and 
tingling. Biochemically probably the cause is myoinositol deficiency. 
Sometimes there maybe associated myopathies, weakness of muscles. 
 
5. Diabetic gangrene: Cause is due to diminished blood supply due to 
atherosclerotic changes in blood vessels.Also associated tissue hypoxia due to 
formation ofHbA1C (glycosylated Hb), less oxygen carrying capacity. 
 
6. Skin lesions: Prone to infections: boils/ulcers and carbuncles. There may be 
• Necrosis of skin 
• Necrobiosis diabetic orum 
• Punctate depigmented atrophy 
• Wound healing is delayed 
 
7. Pulmonary tuberculosis: Susceptible to pulmonary tuberculosis. 
 
 
 
 
 
 
  
 
POSTOPERATIVE OUTCOMES MEASURED: 
 The outcomes that were primarily measured were postoperative infections 
and its complications which include surgical site infections, pneumonia, 
urinary tract infection,  and or sepsis developed on postoperative day 2 or later 
(i.e., > 36 hours following surgery) 
 
Urinary Tract Infections 
 Urinary tract infection was defined by the Centers for Disease Control 
and Prevention. It is based on a combination of symptoms, such as  
• Urgency 
• Frequency 
• Dysuria 
• Urine culture with greater than 105 colonies/mL and no more than 2 
species of organisms.  
The most common causative organisms causing urinary tract infections in 
hospitalised patients are as follows: 
1. Escherichia coli 
2. Klebsiella 
3. Enterobacter 
4. Serratia 
5. Proteus 
  
6. Providentia 
7. Pseudomonas aeruginosa 
8. Alcaligenes 
9. Acinetobacter 
10. Moraxella 
11. Streptococcus fecalis 
12. Staphylococcus pyogenes 
13. Streptococcus pyogenes 
14. Salmonella 
15. Neisseria gonorrheae 
16. Mycobacterium tuberculosis 
17. Candida albicans. 
 
Surgical Site Infections 
Wound infections were defined by the Centers for Disease Control and 
Prevention as infections occurring at the site of incision within 30 days 
following surgery with purulent drainage, dehiscence, or cellulitis. Depending 
upon the severity of these infections they were classified as superficial or deep. 
 
 
 
 
  
The most common organisms causing surgical site infections are: 
Aerobes: 
o Staphylococcus aureus 
o Streptococcus pyogenes 
o B. proteus 
o Pseudomonas 
o Coliform bacilli. 
Anaerobes: 
o Streptococci 
o Bacteroides—Nonspore former 
o Clostridium perfringens 
o Clostridium tetani—Spore former 
o Clostridium septicum 
o Clostridium edematiens 
Fungi: 
o Candida. 
o Aspergillus. 
Source of infection may be exogenous(from environment) or endogenous 
(from commensal of body). Open wound may be infected with multiple 
organisms where as closed un drained wound is usually infected with single 
organism like Staphylococcus aureus, Streptococcus pyogenes and so on. 
 
  
Pneumonia 
Pneumonia was defined as inflammation of the lungs, based on clinical 
examination criteria, an organism isolate from sputum culture and sensitivity 
and/or newly occurring radiographic changes following surgery. Pneumonia 
was included in the outcome measure only if the patient develops pneumonia 
postoperatively and was documented no pneumonia in the preoperative period.  
Overall, any respiratory infection in diabetic patients is associated with 
increased mortality.  Diabetic persons are four times more likely to die from 
pneumonia than non-diabetic patients.  Specific infections, such as those caused 
by Staphylococcus aureus and gram negative organisms, are more frequent in 
diabetes.  According to one study, up to 30% of diabetics are nasal carriers of S. 
aureus as compared with 11% of healthy individuals.  On the basis of their high 
nasal carriage rate, diabetic persons are thought to be at an increased risk for 
S.aureus pneumonia.  More common organisms, such as Streptococcus 
pneumonia, Legionella, and influenza are associated with increased morbidity 
and mortality.   It is yet to be proved that whether Legionella and influenza 
causes pneumonia in diabetic patients with increased frequency or causes a 
severe form of pneumonia in these persons. 
More frequently both gram-negative microorganisms and fungi cause 
pneumonia in patients with diabetes.  The management is similar for both 
diabetics and non-diabetics for bacterial pneumonia.For pneumonia caused by 
influenza antiviral agents are usually prescribed for these persons.   
  
Several studies has also documented increased incidence and high 
prevalence of tuberculosis among diabetic patients.  Diabetes acts as an 
independent risk factor for respiratory tract infections.  Hence strict glycaemic 
control is needed in all diabetic patients especially those who undergo surgeries. 
 
Sepsis 
Sepsis was characterized by fever, elevated leucocyte count and 
sometimes with hypotension, shock, and/or bacteraemia requiring management 
with broad-spectrum antibiotics and other supportive measures for a longer 
duration. 
 
Severe bacterial infections or septicaemia induce septic shock. It may be 
the result of Gram negative septicaemia (endotoxic shock) which is 
morecommon or Gram-positive septicaemia (exotoxic shock).  The most 
common organisms causing sepsis in diabetic patients undergoing various 
surgical procedures are: 
Gram-negative septicaemia (endotoxic shock) e.g. Infection with  
o E. coli 
o Proteus 
o Klebsiella 
o Pseudomonas 
o Bacteroides 
  
Gram-positive septicaemia (exotoxic shock) e.g. Infection with 
o Streptococci 
o pneumococci 
Septic shock results most often from Gram-negative bacteria entering the 
body from genitourinary tract, alimentary tract, respiratory tract or skin, and less 
often from Gram-positive bacteria. In septicshock, there is immune system 
activation and severe systemic inflammatory response to infection as follows: 
 
i) Activation of macrophage-monocytes:  Lysis of Gram negative 
bacteria release endotoxin, a lipopolysaccharide, into circulation where it binds 
to lipopolysaccharide-bindingprotein (LBP). The complex of LPS-LBP binds to 
CD14 molecule on the surface of the monocyte/macrophages whichare 
stimulated to elaborate cytokines, the most important ones being TNF-α and IL-
1. The effects of these cytokines are as under: 
a) By altering endothelial cell adhesiveness: This result in recruitment of 
more neutrophils which liberate free radicals that cause vascular injury. 
b) Promoting nitric oxide synthase: This stimulates increased synthesis of 
nitric oxide which is responsible for vasodilatation and hypotension. 
 
 
 
 
  
 
ii) Activation of other inflammatory responses:  Microbial infection 
activates other inflammatory cascades which have profound effects in triggering 
septic shock. These are as under: 
a) Activation of complement pathway: End-products C5a and C3a induce 
micro emboli and endothelial damage. 
b) Activation of mast cells: Histamine is released which increases 
capillary permeability. 
c) Activation of coagulation system:  Enhances development of thrombi. 
d) Activation of kinin system:Released bradykinin cause vasodilatation 
and increased capillary permeability. 
 
The net result of above mechanisms is vasodilatation and increased 
vascular permeability in septic shock. Profound peripheral vasodilatation and 
pooling of blood causes hyperdynamic circulation in septic shock, in contrast to 
hypovolaemic and cardiogenic shock. Increased vascular permeability causes 
development of inflammatory oedema.Disseminated intravascular coagulation 
(DIC) is prone to develop in septic shock due to endothelial cell injury by 
toxins. Reduced blood flow produces hypotension, inadequate perfusion of cells 
and tissues, finally leading to organ dysfunction. 
 
  
 Septic shock is a grave complication in any person  particularly it is very 
difficult to manage in diabetic patients.  Since patients undergoing surgery are 
more prone to develop hyperglycaemia by various metabolic responses, diabetic 
patients undergoing surgery should be metabolically well controlled to avoid 
this dangerous complication. 
 
DIAGNOSTIC CRITERIA: 
• As per WHO, normal fasting plasma glucose in an adult is 70 to 110 
mg/dl. 
• American Diabetic Association (ADA) recommends the upper limit as 
100 mg/dl, above which the patient has to be tested periodically. 
• HbA1C >6.5%. The test should be performed in a laboratory using a 
method that is NGSP certified and standardized to the DCCT assay. 
• Fasting plasma glucose > 126mg/dl. Fasting is defined as no caloric 
intake for at least 8 hours. 
• 2 hour plasma glucose > 200 mg/dl during an OGTT.  The test should be 
performed as described by the World Health Organisation, using a 
glucose load containing the equivalent of 75g anhydrous glucose 
dissolved  in water. 
• In a patient with classic symptoms of hyperglycaemia or hyperglycaemic 
crisis, a random plasma glucose > 200 mg/dl. 
  
 
 
NORMAL 
PERSONS 
CRITERIA FOR 
DIAGNOSING 
DIABETES 
CRITERIA FOR 
DIAGNOSING 
IGT 
Fasting <110 mg/dl 
<6.1 mmol/L 
>126 mg/dl 
> 7.0 mmol/L 110 to 126 mg/dl 
1 hr after glucose <160 mg/dl 
<9 mmol/L Not defined Not defined 
2 hrs after glucose <140 mg/dl 
< 7.8 mmol/L 
>200 mg/dl 
> 11.1 mmol /L 140 to 199 mg/dl 
 
METABOLIC RESPONSE TO ANAESTHESIA AND SURGERY: 
 Surgery induces a considerable stress response in the perioperative period 
mediated by the neuroendocrine system.  This results in the increased release of 
catecholamines, glucagon, and cortisol in the blood. The principal mechanism 
by which it acts is by stimulating the sympathetic system which results in the 
release of cortisol and catecholamines during surgery. In diabetic patients this is 
affected because of either relative or absolute insulin deficiency, necessitating 
supplemental insulin in the perioperative period. Hence, type 1 DM patients, 
who are at increased risk for end-organ complications, usually need intravenous 
insulin therapy in the perioperative period.  Type 2 diabetes patients may be 
continued on their oral hypoglycaemic agents if they have well controlled 
glycaemic range.   
  
 
These oral hypoglycaemics may be discontinued preoperatively and the 
patient may be started on intravenous insulin therapy depending on the nature of 
surgery and taking into account other associated risk factors. 
Hyperglycaemia may occur even in nondiabetic patients, because of the 
considerable stress response induced by the surgery in the perioperative period.  
It has been shown by multiple randomized controlled studies that achieving a 
strict glycaemic control in all surgical patients has a greater impact on the 
outcome of these patients particularly those who are critically ill. 
By affecting the sympathetic tone several anaesthetic agents will also 
affect the glucose metabolism. Several studies suggested that inhalational agents 
have shown to suppress insulin secretion. This resulting insulin insufficiency or 
relative deficiency often results in dysregulation of the glucose metabolism and 
hyperglycemia. This deficiency along with insulin resistance in diabetic patients 
raises the risk of ketoacidosis in this group.  To mitigate these concerns, the use 
of regional anaesthesia or peripheral nerve blocks has been advocated.  But 
there is a lacking evidence to support that these forms of anaesthesia are 
associated with improved postoperative survival in patients with DM. 
 
  
As there is a rising need for surgical procedures in the diabetes patients so 
is the increasing postoperative morbidity and mortality in these patients. The 
incidence of perioperative ketoacidosis and/or hyperosmolar syndrome is 
increased in these patients in response to the stress of the surgery and its 
resultant complications such as hyperglycaemia, osmotic diuresis and hypo 
insulinemia.  Hyperglycemia results in the impairment of leukocyte function 
and normal wound healing. Our primary goal in the perioperative period is to 
achieve an optimized glycaemic control by serial monitoring, adequate 
hydration, sufficient caloric replacement and judicious utilisation of insulin 
administration. 
 
The need for various surgical procedures is higher in patients with 
diabetes when compared with the non-diabetic people.  Oral hypoglycaemic 
agents cannot be used during the period of fasting required preoperatively in 
major surgical procedures.  Metabolic perturbations resulting from the stress of 
surgery result in the alteration of glucose homeostasis with resultant persistent 
hyperglycaemia.These changes ultimately result in endothelial dysfunction, 
impaired wound healing,sepsis in the postoperative period, and end organ 
damage including cerebral ischemia. Diabetic crises such as diabetic 
ketoacidosis, hyperglycaemic hyperosmolar syndrome may be precipitated by 
the stress response induce by the surgery either during the procedure or 
  
perioperatively with negative prognostic consequences. Several studies have 
documented hyperglycaemic hyperosmolar syndrome as a most noted 
complication after some surgical procedures such as cardiac bypass surgery 
with a mortality rate of 42%. 
Additionally, gastrointestinal instability triggered by anaesthesia, 
medications, and stress-related vagal overlay may result in nausea, vomiting, 
and dehydration. This in addition to the volume contraction that is already 
present from osmotic diuresis provoked by hyperglycaemia may add additional 
complications by increasing the risk for ischemic events and acute renal 
shutdown. There is also an increased risk for arrhythmias in these patients 
because of the deficits in electrolytes, principally potassium and to a little extent 
magnesium also.  These deficits are added to the burden of the risks of coronary 
artery disease in elderly and also in middle ages patients suffering from 
diabetes. 
It therefore becomes essential in people with diabetes who undergo 
surgical procedures to pay careful attention to their metabolic status.  It is 
imperative that whenever elective surgical procedures are planned in people 
with uncontrolled glycaemic status, it should be deferred until acceptable 
glycaemic control is achieved. Admitting these patients prior i.e. one or two 
days before the planned procedure to achieve the desired glycaemic control is 
advisable.Whenever possible, even emergency surgical procedures can be 
  
delayed for better stabilisation of these patients perioperatively and also to 
avoid diabetic crises in such patients. 
Based on the individual’s diabetes class, their regular diabetes regimen, 
current glycaemic state, nature of the undergoing surgical procedure & its 
extent, it is advisable to make the treatment recommendations individualised.  
Whenever feasible some generalised recommendations can be applied however.  
It is imperative to look for electrolytes deficits, hyperosmolar state and diabetic 
ketoacidosis preoperatively and should be corrected whenever possible before 
the surgery and the procedure should be delayed taking into consideration of the 
various factors causing diabetic crises. 
 
STRESS RESPONSE AND GLUCOREGULATION 
Anaesthesia and surgery induced metabolic stress response cause 
hyperglycaemia even in non-diabetics. In patients with diabetes who already 
have abnormalities in glucose metabolism this stress response will compound to 
the complications that are already affecting their homeostatic mechanisms.  The 
invariant features of the metabolic stress response include release of the 
catabolic hormones epinephrine, norepinephrine, cortisol, glucagons, and 
growth hormone and inhibition of insulin secretion and action. 
  
 
Surgical Stress & Its Anti Insulin Effects 
The circulating stress hormones induced by the surgical stress causes 
insulin resistance and also have a deleterious effect on the normally functioning 
β-cell of the pancreas. During surgery the plasma insulin levels decreases and in 
addition the insulin secretory responses to glucose also become impaired.  It has 
not been well established how surgery causes impairment of β-cell 
responsiveness since this defect has not a clear correlation with the circulating 
catecholamine levels during surgery.However it has been documented that there 
is an inverse correlation between the insulin secretory response and the plasma 
epinephrine levels in the postoperative period. 
 
The physiological anabolic and anti-catabolic actions of insulin are 
altered by the metabolic stress response induced by surgery and its anti-insulin 
effects.  The following important anabolic actions of insulin are either reversed 
or attenuated by the surgery induced metabolic stress response. 
• stimulation of glucose uptake and glycogen storage 
• stimulation of amino acid uptake and protein synthesis by skeletal 
muscle 
• stimulation of fatty acid synthesis in the liver and storage in 
adipocytes 
• Renal sodium reabsorption and intravascular volume preservation.  
  
 
The anti-catabolic effects of insulin that are altered include: 
• inhibition of hepatic glycogen breakdown 
• inhibition of gluconeogenesis 
• inhibition of lipolysis 
• inhibition of fatty acid oxidation and ketone body formation 
• Inhibition of proteolysis and amino acid oxidation.  
 
Therefore through a wide variety of physiological mechanisms the 
perioperative milieu is being shifted towards hyper catabolic state by reduced 
insulin secretory response and by affecting the normal physiological actions of 
insulin. 
 
Stress Hormones & Its Catabolic Effects 
Anaesthesia and surgery induced neuroendocrine response to the 
metabolic stress will cause activation of counter-regulatory hormones. The 
catecholamines are released and their circulating levels increase in the 
perioperative period.  It is interestingly noted that during surgery it is the 
norephinerphrine that is augmented and in the postoperative period it is the 
ephinephrine.  Some of the hyperglycemic hormones that are released in the 
circulation which have anti-insulin effects are: 
  
• Glucagon 
• Ephinephrine or Adrenaline 
• Glucocorticoids 
• ACTH 
• Growth Hormone 
• Thyroxine 
  The metabolic effects of these hormones include: 
• Stimulation of  gluconeogenesis and glycogenolysis 
• Inhibition of glucose utilization by peripheral tissues 
• Inhibition of insulin secretion.  
• Activation of phosphoproteins by cAMP-dependent protein kinases 
on liver and muscle glycogen breakdown. 
• Phosphorylation of glycogen synthase resulting in decreased 
glycogen synthesis. 
• Increases adipocyte cAMP levels, leading to phosphorylation and 
activation of hormone-sensitive lipase, which in turn promotes 
lipolysis and release of free fatty acids in the circulation. 
• Causes ketogenesis 
These effects in addition to the stimulatory effects of catecholamines on 
glucagon secretion predispose to severe hyperglycemia.  
  
Similar to the catabolic actions of catecholamines, glucagon whose 
plasma level is increased by the metabolic stress also exhibits catabolic effects 
such as:  
• Stimulation of hepatic glucose production  
• Ketogenesis 
• Inhibition of insulin action in peripheral tissues.  
The catabolic actions of glucagon and catecholamines are exacerbated by the 
glucocorticoids and growth hormone.Glucocorticoids cause: 
• Increase in hepatic glucose production  
• Induce lipolysis 
• Causes negative nitrogen balance by stimulating proteolysis.  
• Free fatty acids, glycerol, glutamine, alanine, etc. which are the products 
of lipolysis and proteolysis acts as substrates for gluconeogenesis thereby 
increasing plasma glucose level. 
METABOLISM INSULIN GLUCAG-ON GLUCOCOR
-TICOIDS 
GROWTH 
HORMONE 
Glycolysis Stimulation   Inhibition 
Gluconeogenesis Inhibition Stimulation Stimulation Stimulation 
Glycogen 
synthesis Activation Inhibition   
Glycogenolysis Inactivation Activation   
Lipolysis Inhibition Stimulation Stimulation Stimulation 
Ketogenesis Inhibition Stimulation  Stimulation 
Protein 
Breakdown Inhibition  Stimulation  
Protein synthesis Anabolism  Catabolism Anabolism 
Blood glucose 
level Decreases Increases Increases Increases 
  
 
The blend of relative hypo insulinism, insulin resistance and catabolic 
effects of counter-regulatory hormone is a genuine risk to the diabetic patients 
with resultant disastrous effect in their glucose homeostatic mechanism, 
especially in those with poorly controlled glycaemic status in the perioperative 
period.It is therefore practical that vast majority of diabetic patients undergoing 
surgery will require insulin therapy in the perioperative period for better 
glycaemic control. 
 
INSULIN 
The word "insulin" is derived from Latin, insula, meaning island(islet). In 
1869, Langerhans identified the alpha and beta cellsin islets of pancreas. In 
1889, von Mering and Minkowski produced experimental diabetes by 
pancreatectomy. In 1922,Banting and Best extracted insulin from pancreas. 
Insulin was the first hormone to be isolated in a pure form. In 1927, Abel 
crystallized the insulin. In 1954, Sanger studied the amino acid sequence of 
insulin; it was the first protein in which complete amino acid sequencing was 
done. For this workSanger got Nobel Prize in 1958. Insulin is the first protein 
produced by recombinant DNA technology (1982). 
 
  
Mechanisms of Action of Insulin 
1. Insulin Receptors 
Insulin acts by binding to a plasma membrane receptor on the target cells. 
In obesity, the number of receptors is decreased and target tissue becomes less 
sensitive to insulin(diabetes mellitus Type 2). Insulin receptor is a glycoprotein 
with 4 subunits; 2 alpha and 2 beta subunits. The alpha units(135 kD) are 
located on the extracellular side, to which insulin binds. The beta subunits (95 
kD) traverse the membrane and are exposed on the cytoplasmic side. Beta 
subunit has tyrosine kinase activity. 
 
2. Signal Transduction 
Insulin binds to the alpha subunit. This binding activates the tyrosine 
kinase activity of the beta subunit, leading to auto phosphorylation of the beta 
subunit. This event, inturn, phosphorylates insulin receptor substrates (IRS). 
The message is later transmitted into a series of serine/threonine kinases, such 
as IRS → Ras → Raf → MAPK, etc. which causes cellular responses. 
3. Gene Transcription (new enzyme synthesis) 
Insulin acts at the transcriptional level to regulate synthesis of more than 
100 proteins. 
3-A. Insulin induces the following enzymes: 
i. Glucokinase 
ii. Pyruvate kinase 
  
iii. Phosphofructo kinase 
iv. Acetyl CoA carboxylase 
 
3-B. Insulin represses the following enzymes: 
i. Glucose-6-phosphatase 
ii. Phosphoenol pyruvate carboxy kinase 
iii. Fructose-1,6-bisphosphatase 
 
4. Activation of Enzymes 
Insulin activates the existing molecules of enzymes by covalent 
modification (phosphorylation or dephosphorylation). There are more than 50 
enzymes activated by this mechanism. Insulin activates protein phosphatase I 
(PPI) which dephosphorylates enzyme proteins. 
 
5. DNA Synthesis 
Through the IRS-1 pathway, insulin increases DNA synthesis, cell 
growth and anabolism. In all the above mentioned pathways, intracellular 
mediators have been implicated in insulin action. These are Ca++ and cyclic 
AMP. Insulin activates phosphodiesterase and thereby decreases cAMP. So, 
reactions dependent on cAMP are inhibited, e.g. glycogen phosphorylase. 
 
 
  
6. Glucose Uptake 
Insulin increases the recruitment of GluT4 in cells. 
Metabolic actions of Insulin: 
Insulin plays a central role in regulation of the metabolism of 
carbohydrates, lipids and proteins. 
 
1. Uptake of Glucose by Tissues 
Insulin facilitates the membrane transport of glucose. Facilitated diffusion 
of glucose in muscleis enhanced by insulin. In diabetes mellitus, the transporter, 
GIuT4 is reduced. However, glucose uptake in liver (by GluT2) is independent 
of insulin. 
 
2. Utilization of Glucose 
i. Glycolysis is stimulated by insulin. The activity and amount of key 
glycolytic enzymes (glucokinase, phosphofructokinase and pyruvate kinase) are 
increased. 
ii. Glycogen synthase enzyme is activated, and so insulin favours glucose 
storage as glycogen. 
iii. Insulin favours synthesis of fatty acid from glucose and so glucose 
utilization is increased. 
 
  
3. Hypoglycemic Effect 
i. Insulin lowers the blood glucose level by promoting utilization and 
storage. 
ii. Gluconeogenesis is inhibited by insulin by repressing the key enzymes, 
pyruvatecarboxylase (PC) phosphoenol pyruvate carboxykinase (PEPCK) and 
glucose-6-phosphatase. 
iii. Insulin inhibits glycogenolysis by favouring the inactivation of 
glycogen phosphorylase and inhibiting glucose-6-phosphatase. The net effect of 
all these three mechanisms, blood glucose level is lowered. 
 
4. Lipogenesis 
i. Lipogenesis is favoured by providing more acetylCoA by pyruvate 
dehydrogenase reaction. 
ii. Insulin increases the activity of acetyl CoA carboxylase and provides 
glycerol for esterification of fatty acids to TAG. 
iii. Insulin also provides NADPH by increasing theGPD activity of the 
HMP shunt pathway. 
 
5. Anti-lipolytic Effect 
i. Insulin inhibits lipolysis in adipose tissue due to inhibition of hormone 
sensitive lipase. 
  
ii. The increased level of FFA in plasma in diabetes is due to the loss of 
this inhibitory effect on lipolysis. 
 
6. Anti-ketogenic Effect 
i. Insulin depresses HMG CoA synthase and so ketogenesis is decreased. 
 
GLYCATED HEMOGLOBIN 
Glycated haemoglobin (HbA1c) was formerly known as an “unusual” 
haemoglobin in diabetic patients above 40 years of age.  Numerous studies had 
been conducted since then and its correlation with plasma glucose levels was 
established.  This resulted in using HbA1c as an objective measure of long term 
glycaemic control in diabetic patients. The widely known A1C-Derived 
Average Glucose (ADAG) study involved 643 members expressing a wide 
range of A1C levels. This study proved the strong correlation between A1C 
level and plasma glucose levels among the population studied.  After this 
HbA1c was introduced in the 1980s in clinical practice and consequently has 
remained a cornerstone in the management of diabetic patients. 
 HbA1c levels correlates with long term glycaemic status of an individual 
as it reflects mean plasma glucose levels over the past eight to twelve weeks. It 
can be done at any period of the day and does not need any special preparation 
  
like fasting. These qualities have made HbA1c as the favourite test for assessing 
glycaemic control in diabetic patients.  In recent times, there has been an 
increasing interest in utilising it as a screening test for high risk patients prone 
to diabetes and also as a diagnostic test in patients with diabetes. 
The practical difficulties that have been encountered in measuring fasting 
blood glucose levels, in performing oral glucose tolerance test, and the daily 
variability in plasma glucose in diagnosing diabetes had led us to the search for 
an alternative.  HbA1c overcomes these problems in the clinical practice 
making it practically plausible.  ADA now recommends HbA1c as a means in 
diagnose diabetes.Even though the sensitivity and specificity is almost equal to 
the plasma glucose measurement in predicting chronic complications of 
diabetes such as diabetic retinopathy, it is still not available in most of the parts 
of the world.It has also been seen that patients diagnosed as having diabetes on 
the basis of HbA1c may not have diabetes by plasma glucose measurements. 
If stringent quality assurance tests and assays are standardised to the 
international reference values, HbA1c can be used as a diagnostic test for 
diabetes. 
The cut off for diagnosing diabetes on the basis of HbA1C is 6.5%. 
HbA1C values less than 6.5% does not exclude diabetes already identified on 
the basis of plasma glucose measurements. 
  
 The advantages of using HbA1c are: 
• Avoids the difficulty faced by day to day plasma glucose 
variability. 
• Evades the need for the patient to fast and/or to have special 
dietary preparations preceding the test. 
 These benefits have made it an ideal tool for early diagnosis and 
treatment which have been strongly advocated in recent years.  
 Nevertheless, HbA1c may be affected by a variety of factors such as 
hereditary, haematological, other existing comorbid illnesses.  Some of the most 
common variables affecting the HbA1c levels worldwide are: 
• Haemoglobinopathies 
• Anaemias, and  
• Accelerated red cell turnover (e.g. malaria) 
 Presently it is necessary to weigh the benefits and convenience of 
utilising HbA1c in diagnosing diabetes against the plasma glucose 
measurement, as it is not available currently in most parts of the world, even 
though it has been acknowledged as an ideal test in the management of diabetes.  
And also it needs further standardisation to recommend its use universally.  It is 
  
not a distant dream as many countries have already optimized its use in the 
clinical practice in diabetes management. 
It is the global consistency that remains as a problem, even though 
HbA1c and plasma glucose measurement is similar in most laboratories. 
Whatever is used i.e. either plasma glucose or HbA1c, international 
standardisation is required to achieve consistent and comparable values.  
Despite it started happening in most of the countries, it has not become a 
standard all over the world. 
 The following programs have attempted for international standardisation 
and improved harmonization in measuring HbA1c levels across various 
manufacturers:  
• The National Glycohaemoglobin Standardization Program (NGSP) being 
established on accomplishment of Diabetes Complications and Control 
Trial has remained as a basis for improved harmonisation. 
• International Federation of Clinical Chemists (IFCC) has recently 
established a working group to introduce an international standardization 
program.  
 
  
Because of these efforts, reference method procedures are being established 
for HbA1c assays.  At present NGSP and IFCC, to enhance the standardisation 
and harmonisation, base their findings on reference method procedures for 
HbA1c levels. 
Apart from standardisation, the cost and availability across many 
countries across the world is another important concern. In addition the 
prevalence of factors affecting HbA1c levels such as haemoglobinopathies in 
several countries also affect its measurement as already mentioned. 
A report published in 2009 by an International Expert Committee on the 
role of HbA1c in the diagnosis of diabetes recommended the following: 
• HbA1c level > 6.5% to diagnose diabetes. 
• Diagnosis should be confirmed with a repeat HbA1c test, unless clinical 
symptoms and plasma glucose levels >11.1mmol/l (200 mg/dl) are 
present in which case further testing is not required.  
• Levels of HbA1c just below 6.5% may indicate the presence of 
intermediate hyperglycaemia.  
• The precise lower cut-off point for this has yet to be defined, although the 
ADA has suggested 5.7 – 6.4% as the high risk range. 
• Persons with HbA1c level between 6.0 and 6.5% were at particularly high 
risk and might be considered for diabetes prevention interventions.  
  
To establish the predictive value of plasma glucose and HbA1c level in 
diagnosing micro and macrovascular complications of diabetes further studies 
are needed.  It is required to establish a working group to observe various 
factors affecting HbA1c and plasma glucose measurement among all major 
ethnicities.  
 A single abnormal value of either plasma glucose measurement or HbA1c 
is not enough to make the diagnosis of type 2 diabetes in an asymptomatic 
person. The diagnosis is confirmed with either one more abnormal plasma 
glucose or HbA1c measurement at least from a random sample, or from fasting 
sample or from abnormal oral glucose tolerance test which should be in the 
diabetic range.   
 Either one test is enough to make the diagnosis, but if both plasma 
glucose and HbA1c are available and both are in the diabetic range, then the 
diagnosis is confirmed. It is not advisable to confirm the diagnosis on the basis 
of only one abnormal result.  It is mandatory for another abnormal test value to 
diagnose a patient with diabetes. 
 The diagnostic certainty is vital because of the increasing screening 
programmes by which many more asymptomatic persons are being identified to 
have diabetes.  In such individuals if the screening tests do not confirm the 
diagnosis, continued surveillance through periodic screening is essential to 
  
include or exclude the patient in the diabetes group as defined earlier for 
appropriate management. 
 
Association of HbA1c Levels and Mean Plasma Glucose Levels 
HbA1c Level, % 
Mean Plasma Glucose Level, mg/dl 
(mmol/L) 
6 135 (7.5) 
7 170 (9.5) 
8 205 (11.5) 
9 240 (13.5) 
10 275 (15.5) 
11 310 (17.5) 
12 345 (19.5) 
 
 
 
 
 
  
PREOPERATIVE BLOOD GLUCOSE EFFECTS ON 
INTRAOPERATIVE CARE 
 The major factors which play an important role in the intraoperative 
glycaemic control are the oral hypoglycaemic agents, insulin therapy and the 
HbA1c levels.  At present there are no defined standard guidelines for 
preoperative plasma glucose range; however few important inferences are made 
from various research studies.All patients with diabetes should always have a 
preoperative fasting blood glucose value even if they have well controlled 
glycaemic status and when glucose level is above 180 mg/dl, it is ideal to start 
insulin therapy for a better glycaemic control in the perioperative period.  
The better long term glycaemic control is being established by HbA1c 
value less than 7%.  With good glycaemic control the postoperative infections 
and its complications are less.  In patients with poorly controlled blood glucose 
as indicated by HbA1c levels ≥7% need gradual reduction of blood glucose with 
careful surveillance.  Oral hypoglycaemic agents such as sulfonylureas, 
biguanides, thiazolidinediones are not routinely used in the perioperative period 
for glycaemic control since they have the propensity to induce 
hypoglycaemia.With the knowledge of the metabolic stress induced by 
anaesthesia and surgery, diabetes patients are advised to stop the oral 
hypoglycaemics one day prior to the surgical procedures.  For emergency 
  
surgical procedures, diabetic patients on oral hypoglycaemics are prone to more 
complications, since they are ill prepared. Some examples for these are: 
• Biguanides cause lactic acidosis, hepatic and renal failure in 
hypoperfused condition and hence it is imperative to stop it 48 
hours prior to surgery. 
• Sulfonylureas with a potassium-channel-blocking effect impede the 
myocardial ischemia pre conditioning. Patients on sulfonylureas 
who undergo coronary angioplasty have been proved to have a 
higher mortality rate than those who receive insulin preoperatively.  
Similarly greater mortality rate has been established among 
diabetes patients on sulfonylureas during the time of myocardial 
infarction. 
With recent advances in the improved glucose monitoring and the 
availability of different types of insulin, the recommendations of preoperative 
insulin therapy have been changed.  The rational thinking now is that the 
originally advised one half of the insulin dose required in the morning of day of 
surgery will not be appropriate in the current settings.  When the patient is in nil 
per oral, the blood glucose should be monitored and treated with short-acting 
insulin preoperatively.  Diabetic patients undergoing surgery who are on basal 
insulin regimen should be continued on their dose until the day of surgery.  In 
  
patients on nil oral, it is necessary to supply enough calories by infusing 5% 
dextrose and hourly plasma glucose monitoring. 
The acceptable range of glycaemic control is not clearly yet defined, but 
it has been clearly established that intraoperative management with intravenous 
insulin infusion has reduced the unwanted metabolic and infectious 
complications associated with hyperglycaemia. The micro and macro vascular 
complications associated with diabetes have been shown to be decreased by 
long term intensive glycaemic control.  The best and least complicated way for 
blood glucose control in diabetic patients is by dietary carbohydrate restriction 
as it is associated with less chance of hypoglycaemic crises.As insulin activity 
depends on GLUT4 glucose transporter, dietary restriction is the advisable 
efficient way in maintaining glycaemic control. 
Nowadays many advanced anaesthetic and surgical techniques have been 
introduced that minimises the metabolic stress response, thereby mitigating the 
hyperglycaemic response.For example minimally invasive surgical techniques 
and neuro axial anaesthesia alleviates the metabolic stress response.  The 
duration and the technique of the surgical procedure have a strong direct 
correlation with reduced insulin sensitivity induced by the surgery. Thorell and 
co workers compared conventional open cholecystectomy with that of 
laparoscopically performed cholecystectomy and demonstrated that 
laparoscopic procedure which is minimally invasive showed less reduction in 
  
insulin sensitivity. General anaesthesia produced higher concentration of 
circulating stress hormones when compared with either local and/or epidural 
anaesthesia.  Moreover, volatile anaesthetics utilised in induction and 
maintenance of general anaesthesia increase glucose synthesis in liver and 
inhibit insulin secretory response thereby causing hyperglycaemia.Preoperative 
glycaemic control is mandatory for an optimal intraoperative management of 
diabetic patients.  In uncontrolled diabetes i.e. in patients with plasma glucose 
levels above 300 mg/dl it is difficult to achieve normo glycaemia preoperatively 
and requires stringent monitoring to avoid complications. 
POSTOPERATIVE INFECTIONS IN DIABETICS: 
 Hyperglycaemia is strongly associated with poor postoperative outcomes 
in hospitalised patients in both diabetic and non-diabetic patients.  Recent 
studies suggested that vigorous control of blood glucose level to maintain in 
euglycaemic range is related to decreased perioperative morbidity and mortality. 
 Pomposellie et al established the correlation between perioperative 
glycaemic control and postoperative infection by an extensive study in 100 
patients with diabetes undergoing surgical procedures electively.  The important 
conclusions obtained from their research were: 
• Single blood glucose value more than 220 mg/dl on the first postoperative 
day was a sensitive (87.5%) predictor of postoperative infection.   
  
• Patients with blood glucose values >220 mg/dl had infection rates that 
were 2.7 times higher than the rate for patients with lower blood glucose 
values.   
• When minor infections were excluded, the relative risk for serious 
postoperative infection, including sepsis, pneumonia, and wound 
infections, was 5.7 times higher than those with glucose levels less than 
220 mg/dl. 
Particularly in diabetic patients who undergo coronary artery bypass 
graft, diabetes poses a considerable independent risk factor. Perioperative 
hyperglycaemia is related with a greater risk of deep sternal wound 
infections and increased mortality.  Strict glycaemic control in patient 
undergoing coronary artery bypass graft resulted in better postoperative 
outcomes. Furnary et al stated that maintaining the glycaemic range within 
150 to 200 mg/dl by perioperative insulin infusion regimen is associated 
with a substantial (59%) reduction in risks associated with deep sternal 
wound infections when compared with the standardized control group. 
 
 Several mechanisms have been stated for poor clinical outcomes in 
diabetic patients with hyperglycaemia in the perioperative period. Neverthless, 
the exact reasons are not yet clearly established.  More interest has been laid 
  
upon the poor wound healing rate and increasing infection rates. 
Hyperglycaemia has certain potential impacts on the body’s immune system and 
affects normal physiological wound healing by various modes such as: 
• Impaired leukocyte function 
• Decreased phagocytosis 
• Impaired bacterial killing 
• Defective chemotaxis 
• Inhibition of polymorphonuclear leukocyte respiratory burst 
• Diminished superoxide generation 
• Inhibition of phospholipase D activity 
• Altered complement function 
• Impaired collagen synthesis 
• Reduced wound tensile strength 
• Reduced neovascularisation at the wound site 
• Reduced capillary volume at the site of injury 
 
 
 
  
Many randomised controlled trials and various research studies have 
established the direct relationship between the incidence postoperative 
infections with perioperative glycaemic control.  Postoperative blood glucose 
values more than 200 mg/dl have a 17 to 86% increased risk for infectious 
complications.  Leucocyte functions are known to be improved by achieving a 
normal glycaemic range by insulin therapy thereby decreasing the risk for 
systemic and local infections.  In diabetes it is the advanced glycosylation end 
products that accumulate which adversely affect the cellular function, formation 
of extracellular matrix, synthesis of cytokines and thereby preventing normal 
wound healing. 
 
GLYCAEMIC GOAL DURING THE PERIOPERATIVE PERIOD 
 The recommendations made by American Diabetes Association and 
American Association of Clinical Endocrinologists are: 
• Critical care patients should be maintained on glycaemic range within 80-
110 mg/dl.   
• Pre-prandial blood glucose < 110 mg/dl and random blood glucose < 180 
mg/dl were recommended for non-critically ill patients. 
 
 
 
  
METHODS OF ACHIEVING GLYCAEMIC CONTROL 
 As many perioperative complications have been documented in diabetic 
patients with poorly controlled glycaemic status, it is imperative to vigorously 
monitor the plasma glucose level and maintain it in the desirable range while at 
the same time avoiding hypoglycaemia.Patients on oral diabetic agents prior to 
surgery may resume their earlier regimen in the postoperative period after 
careful assessment.However the risk-benefit ratio of oral hypo glycaemics 
should be thoroughly weighed before because of the possible unwanted 
complications.  The most easily titratablility and flexibility made intravenous 
insulin therapy as the perfect modality for glycaemic control in the 
perioperative period. 
Ideally all diabetic patients undergoing various surgical procedures 
should be on intensive management of diabetes perioperatively. Patients 
undergoing surgery are operationally managed by combined insulin, dextrose 
and potassium therapy.  Any surgery which requires general anaesthesia more 
than one hour is defined as major surgery.  Management of patients with type 2 
diabetes is usually based on their regular diabetes regimen, glycaemic status, the 
nature and the duration of the procedure and also the expertise available. 
Dietary Management 
Dietary carbohydrate restriction and regular physical exercises alone is 
sufficient for diabetic patients with good glycaemic control.  On the day of 
  
surgery, fasting blood sample should be measured.  Intraoperative monitoring of 
plasma glucose is required for any surgery extending more than one hour.For 
minor surgical procedures their regular regimen will be appropriate and may not 
need any special intervention.  For major surgeries and patients with poorly 
controlled diabetes i.e. plasma glucose level more than 200 mg/dl, intravenous 
insulin therapy combined with dextrose is required with periodic intraoperative 
glucose monitoring. 
Managements with Oral Hypoglycaemic Agents 
There are some special considerations for patients managed with oral 
anti-diabetic agents.  Sulfonylureas are discontinued one day prior to surgery 
except chlorpropramide.  Chlorpropramide is discontinued at least 2 to 3 days 
before surgery. Despite metformin having short half-life i.e. 6 hours, it is 
advisable to stop it 1 to 2 days prior to surgery, especially in patients with hypo 
perfused state as there is an increased risk for lactic acidosis, tissue hypoxia and 
renal failure.  Other oral hypoglycaemics may be continued till the day of 
surgery. 
It is ideal to monitor the blood glucose levels at least before and 
immediately after the procedure in every diabetic patient. Hourly monitoring is 
mandatory for patients undergoing major surgical procedures followed by 
immediate postoperative value.  Capillary blood glucose measurements 
available by bedside glucose meters are sufficient for postoperative monitoring 
  
and management.  Only in cases reported to have high variability either in the 
form of hyper or hypoglycaemia require blood glucose measurement by a 
standard laboratory before starting specific therapeutic management. 
 
Class of Oral Agent Example Considerations 
Alpha-glucosidase 
inhibitors 
Acarbose Inhibit enzymes that metabolize 
carbohydrates; no benefit if NPO 
Secretagogues (eg, 
sulfonylureas, 
meglitinides) 
Glyburide, 
glimepiride 
Hypoglycemia, prolonged action, may be 
unpredictable, difficult to titrate 
Biguanides Metformin Increased risk for lactic acidosis; Cautious 
use in hepatic and renal failure, congestive 
heart failure; available in combination 
therapy 
  
Thiazolidinediones Rosiglitazone Increased intravascular volume (CHF), 
slow onset of effect, difficult to titrate 
Dipeptidyl peptidase-4 
(DPP-4) inhibitor 
Sitagliptin Slows inactivation of incretin hormones to 
enhance physiologic glucose control; 
dosage reduction required for renal 
insufficiency 
Perioperative blood glucose values more than 200 mg/dl is usually 
managed with small doses of subcutaneous short-acting insulin with careful 
watch for hypoglycaemia.  Oral anti diabetic agents can be resumed following 
minor surgeries immediately following oral intake usually without any 
complications. Patients on metformin are restarted only after 72 hours after 
surgery or any iodinated radio contrast procedures performed.  It is ideal to 
resume metformin therapy after properly establishing normal renal function and 
in the absence of nephropathy caused by contrast studies.The optimal 
recommendations for managing patients with poorly controlled blood glucose 
levels and who underwent major surgical procedures is by intravenous insulin 
therapy with dextrose usually following either of the two standard regimens as 
mentioned later in this text. 
  
Insulin Therapy 
Minor surgery 
Ideally patients on long-acting insulin therapy such as ultra lente, 
glargine, protamine zinc insulin is substituted with intermediate-acting insulin 1 
to 2 days prior to elective surgical procedures.  Vigilant monitoring of 
perioperative glucose levels is vital to prevent extremes of 
glycaemia.Intravenous insulin/glucose/potassium should be started prior to 
surgery. Blood glucose monitoring should be done hourly during the procedure 
and one immediately following surgery.  Intravenous insulin infusion should 
ideally be stopped once oral intake is resumed and the regular regimen should 
be reinitiated.It is ideal to have an hour overlap in between stopping insulin 
infusion and restarting subcutaneous insulin. 
 
 
Major surgery 
Ideally patients treated with insulin who undergo major surgical 
procedures should be admitted 2 to 3 days prior to surgery, if glycaemic status 
is not in the desirable range i.e. HbA1c more than 8%.  If the patient could not 
be admitted, self monitoring of blood glucose should be taught to the patient to 
optimize the blood glucose value to the euglycaemic range in the preoperative 
period.  Self monitoring is advisable before every meal and before sleep.  The 
  
recommended pre prandial range is between 80 to 120 mg/dl and bedtime range 
is between 100 to 140 mg/dl. 
 
The preoperative evaluation of the diabetic patient should include the 
following: 
• Physical examination particularly focusing on cardiac evaluation 
and autonomic neuropathy. 
• Serum blood glucose levels 
• Serum electrolytes 
• Serum creatinine 
• Urinary ketones 
 
 
Increased surveillance is mandatory in patients with autonomic neuropathy 
because of its propensity to cause hypotension, respiratory depression and 
hemodynamic instability. Metabolic and electrolyte imbalance such as acidosis, 
hyponatremia, dyskalemia should be corrected prior to surgery.  
 
Intravenous Insulin, Glucose, Potassium, and Fluids 
Intravenous infusion of insulin, glucose, and potassium is the 
recommended therapy and has substituted subcutaneous insulin therapy for the 
  
perioperative management of diabetes. Many studies have stressed the benefits 
of insulin infusion therapy against subcutaneous insulin. 
As once thought it is not needed to supplement albumin with insulin 
infusion in order to prevent nonspecific adsorption to the infusion apparatus.  
The same thing can be achieved by flushing 50 ml of insulin infusion mixture 
via the tubing. 
Intravascular volume should be maintained with adequate fluid 
administration.  Osmotic diuresis in poorly controlled diabetes may result in 
fluid deficit and should be managed properly for a better perioperative 
management.  The preferred intravenous fluids for replacement are normal 
saline and dextrose solutions.  Solutions containing lactate such as Ringer’s 
lactate, Hartmann’s solution etc. will exacerbate hyperglycaemia. 
Insulin 
There are two methods of insulin infusion that is used currently: 
• Insulin infusion in combination with glucose and potassium in the 
same solution i.e. GIK regimen. 
• Administering insulin separately via an infusion pump. 
Of the above the GIK infusion is the preferred one because it is more 
effective, safe and efficient in most of the patients.  The only drawback is that it 
is not possible to do selective adjustment of insulin dosage.  The glucose 
  
solution usually used in this regimen is 5% dextrose or 10% dextrose.  10% 
dextrose provides more calories. 
Irrespective of whatever means insulin is administered i.e. either by 
combined or separate infusions, continued surveillance of blood glucose level is 
imperative to avoid extremes of glycaemia.  The recommendations of insulin 
therapy should be individualised and should be flexible to adjust the patient 
factors and the nature of the surgical procedure.  The usual universally 
recommended glycaemic range based on evidence based studies is between 120 
to 180 mg/dl. 
 
The rate of initial insulin infusion is estimated as between one-half and 
three-fourths of the total daily insulin requirement expressed in units/h.  In most 
of the type 1 diabetes patient it is ideal to start with 0.5 to 1 unit/h regular 
insulin.  Patients on oral hypoglycaemics requiring perioperative insulin and 
type 2 diabetes patients on insulin therapy can be started with an infusion rate of 
1 to 2 units/h. 
 
Insulin infusion rate of one unit/h achieved either by: 
  
• 25 units of regular insulin mixed in 250 ml of normal saline 
resulting in a solution containing 0.1 unit/ml.  This is infused at the 
rate of 10ml/h. 
• Regular insulin 50 units with normal saline is made to a 50 ml 
solution. This is then administered via an infusion pump at the rate 
of 1ml/h. 
The rate of insulin infusion is so adjusted to maintain the blood glucose 
level in the range of 120-180 mg/dl. 
The duration and nature of the surgery and the degree of glycaemic 
disturbances determine the dose of insulin to be supplemented.  Elective 
surgeries in type 1 diabetes patient should be scheduled as the initial case to 
avoid the variability of blood glucose levels and to minimize the need to change 
their regular regimen.  Patients may be administered half of their regular dose of 
long acting insulin depending upon the nature of their procedure.  They are 
permitted earlier in the preoperative waiting room to have their blood glucose 
checked to determine the need for dextrose infusion. 
Preferably a separate intravenous line is established for insulin infusion 
during surgery.  The rate of insulin infusion is calculated using the following 
formula: 
Insulin (U/hr) = serum glucose (mg/dL)/150 
  
A second intravenous access is required for volume replacement.  
Another intra-arterial cannulation is required to monitor blood glucose levels 
hourly during the procedure and in the postoperative period. 
Several protocols for insulin therapy are widely available without any 
standardisation.  Recently computer based systems are also available to 
calculate the required insulin dose based on blood glucose level and its rate of 
change.  Glucommander introduced was one such system.  In this the initial 
factors and the baseline blood glucose value are given.  The auto programme 
then calculates the rate of insulin infusion and also recommends the periodic 
intervals for further blood glucose monitoring.  This can be repeated 
indefinitely. The amount of insulin required is calculated on the basis of the 
following equation: 
Insulin per hour = multiplier x (blood glucose – 60) 
 
The periodic intervals in which the blood glucose to be monitored is 
detected automatically by the programme.  It is monitored as frequently as 
every twenty minutes or up to maximum interval that is specified.  Practically 
blood glucose levels are monitored every hourly.  The frequency is shortened 
automatically if there is rapid change is blood glucose levels and is lengthened 
when the glycaemic range is maintained in the desired level.  Glucommander 
  
has been proved to very useful in critically ill and also in non-critically ill 
patients.  Studies are still pending to assess the utility of such systems. 
 
 
 
  
 
The clinical status of the diabetic patient determines the duration of 
insulin-dextrose infusion therapy.  Ideally it is continued postoperatively until 
the patients resumes oral feeds.  Once oral intake is established the regular 
diabetic regimen can be reinitiated.  It is necessary to administer first 
subcutaneous dose of insulin postoperatively half to one hour before 
discontinuing the intravenous access.  
 
Glucose 
Sufficient caloric replacement in the form of glucose should be 
administered in patients undergoing surgery to avoid catabolic reactions, 
starvation ketosis and hypoglycaemia.   The normal physiological amount of 
glucose essential to inhibit catabolism in a normal non-diabetic adult is about 
  
120 g/day or 5 g/h. Preoperative fasting, metabolic stress response to 
anaesthesia and surgery and the required insulin therapy in the preoperative 
period all increases the caloric requirement in diabetic patients.  The caloric 
requirement in these patients averages between 5 to 10 g/h of glucose.  This is 
either administered by 5% or 10% dextrose solution.  In patients requiring fluid 
restriction, 10% dextrose is recommended.  An infusion rate of 100 ml/h with 
5% dextrose delivers 5 g/h glucose.  Nowadays it is preferred to administer 10% 
dextrose at an initial infusion rate of 100 ml/h. 
The recommended range of blood glucose level in the perioperative 
period is 120 to 180 mg/dl.  Insulin-dextrose infusion therapy are adjusted to 
maintain in the desired range when there is marked variability.  Normally 0.3 
units of insulin / gram glucose is given for most of the stable patients.  Insulin 
requirements are increased in 
• Sepsis 
• Obesity 
• Unstable patients with comorbid illness 
• Steroid therapy 
• Carido pulmonary bypass surgery. 
 
  
Potassium 
Insulin and glucose infusion causes intracellular translocation of 
potassium thereby increasing the risk of hypokalemia.  In normokalemic 
patients, 10 mEq potassium chloride is routinely added to every 500 ml of 
dextrose to maintain normal serum potassium, if the renal function is adequate.  
Existing hyperkalemia as evidenced by laboratory measurement and 
electrocardiogram and renal failure are contraindication for potassium 
supplementation. 
Emergency Surgery 
Nearly around 5 to 10 % of diabetic patients required emergency surgery 
in their lifetime.  Most commonly performed surgeries include laparotomy, 
cholecystectomy, appendectomy, and similar general surgical procedures.  
Additionally diabetes complicating surgeries such as incision and drainage of 
abscesses, ulcer management and amputations are also performed. 
 
When these emergencies occur, is not predictable and immediate surgical 
intervention should be done without any delay.  It is prudent to exclude diabetic 
ketoacidosis and similar conditions complicating diabetes that mimic surgical 
emergencies.  Patients with DKA present as acute abdomen in the emergency 
and it has been reported to undergone unnecessary exploratory laparotomies.  
Diabetic autonomic neuropathy can affect gastrointestinal tract causing 
  
gastroparesis, intractable vomiting, gastro enteropathy.  These simulate 
abdominal surgical emergencies.  Diabetic pseudotabes syndrome similarly 
causes sharp neuropathic pain along thoracolumbar dermatomes which is 
similar to that of visceral disorders.  Therefore it is essential to take a thorough 
clinical history and physical evaluation in diabetic patients presenting as 
surgical emergency to exclude such pitfalls.  
 
Most of the diabetic patients requiring emergency surgical intervention 
will have poorly controlled glycaemic status.  This should not contraindicate a 
timely performed lifesaving procedure.  Assessment of blood glucose levels, 
serum electrolytes and acid base analysis should be done immediately after 
securing an intravenous catheter.  Any gross abnormalities detected should be 
corrected preoperatively as far as possible to optimise the patient for surgery. 
Whenever possible, surgery should be delayed diabetic ketoacidosis until 
the acid base disorder is corrected.  Intravascular volume replacement and 
improved of metabolic status should be carried out in patients with HHS 
without undue delay as they are significantly dehydrated. Hourly monitoring of 
blood glucose should be done at bedside.  Insulin-glucose-potassium infusion 
therapy should be initiated and titrated appropriately to maintain the glycaemic 
range between 120 to 180 mg/dl. Serum potassium should be monitored every 
  
2nd or 4th hourly and potassium should be supplemented accordingly to maintain 
the patient in eukalemic state during and after surgery. 
Diabetic patients pose specific challenges postoperatively. To reduce the 
adverse events, methods of achieving glycaemic control in the perioperative 
period in these patients should be individualised   in order to achieve an optimal 
result. 
 
 
 
Perioperative management of patients with diabetes: 
I) Minor surgery in DM2 patients not treated with insulin 
● Hold oral agents the day of surgery. 
● Patients with “fair” metabolic control (fasting blood glucose  
180mg/dL)—cover with regular insulin or rapid-acting (lispro, aspart,glulisine) 
insulin as needed. 
● Patients with “poor” metabolic control (fasting blood glucose  
180mg/dL)—start continuous insulin infusion. 
● Goals: avoid excessive hyperglycemia (blood glucose 180 mg/dL) and 
hypoglycemia (blood glucose  80 mg/dL). 
 
II) Minor surgery in DM1 and DM2 patients treated with insulin 
  
● Hold oral agents (if treated with combination therapy) the day of 
surgery. 
● Patients in “fair” metabolic control (fasting blood glucose  180 mg/dL): 
– Give half of intermediate-acting insulin (NPH) the morning of 
the surgery. 
– While NPO, infuse dextrose 5% saline plus KCl (10-20 mEq/L) 
at 100 mL/hour. 
– Check blood glucose every 4 to 6 hours while NPO and 
supplement with short-acting insulin. 
– Patient treated with basal (glargine) insulin should receive their 
usual basal insulin dose. Similarly, patients treated with continuous 
insulin infusion therapy (insulin pump) should receive their usual basal 
infusion rate. 
– Restart preadmission insulin therapy once food intake is tolerated 
● Patients in “poor’ control (fasting blood glucose  180 mg/dL)—start 
continuous insulin infusion. 
 
III) Major surgery in DM1 and DM2 patients treated with insulin 
● Hold oral agents the day of surgery 
● Start continuous insulin infusion prior to surgery and continue during 
perioperative period. 
  
● Goals: Maintain blood glucose  180 mg/dL during surgery, and blood 
glucose between 80 to 120 mg/dL during the perioperative period in the surgical 
intensive care unit. Start subcutaneous insulintwo hours prior to discontinuation 
of insulin infusion. In non-ICU settings, avoid excessive hyperglycemia (blood 
glucose 180 mg/dL)and hypoglycemia (blood glucose 80 mg/dL). 
 
HYPOGLYCAEMIA COMPLICATING GLYCAEMIC CONTROL: 
 While maintaining the patient in strict glycaemic control it is imperative 
to avoid hypoglycaemia and its complications.  Despite advances in the 
treatment of diabetes, hypoglycaemic episodes are often the limiting factor in 
achieving optimal blood sugar control.  The risk of severe hypoglycaemia is 
higher in elderly patients, those having comorbidities such as vascular disease 
or renal failure, pregnant women.  Moreover in type 2 diabetes, progressive 
insulin deficiency, longer duration of diabetes and tight glycaemic control 
increase the risk of hypoglycaemia. 
Hypoglycaemic manifestations usually occurs when the blood glucose 
level is abnormally low, usually less than 70 mg/dl (4mmol/L).Hypoglycaemia 
with decreasing plasma glucose concentration causes a series of signs and 
symptoms by signalling central nervous system which is mediated via 
autonomic nervous system and by decreasing metabolism of neurons.  
Neurogenic symptoms are the result of the perception of physiological changes 
caused by the activation of the autonomic nervous system triggered by 
  
hypoglycaemia.  Although all three efferent components of the autonomic 
nervous system—adreno medullary, sympathetic neural, and parasympathetic 
neural—are activated by hypoglycemia, neurogenic symptoms are thought to be 
caused by sympatho adrenal activation and mediated by norepinephrine released 
from sympathetic adrenergic postganglionic neurons, the adrenal medullae, or 
both, by acetylcholine released from cholinergic sympathetic postganglionic 
neurons and by epinephrine released from the adrenal medullae. Some 
neurogenic symptoms, such as tremulousness, palpitations, and anxiety/arousal, 
are adrenergic (catecholamine mediated); whereas others, such as sweating, 
hunger, and paresthesias, are cholinergic. Awareness of hypoglycemia is largely 
the result of the perception of neurogenic symptoms and the recognition that 
they are indicative of hypoglycemia. Clearly, therefore, awareness of 
hypoglycemia is a function of the knowledge and the experience of the 
individual, as well as the physiological responses to low glucose concentrations. 
Neuroglycopenic symptoms are the result of brain neuronal glucose 
deprivation. They include sensations of warmth, weakness, and fatigue as well 
as difficulty thinking, confusion, behavioral changes (not infrequently confused 
with inebriation by others), and emotional lability. They also include seizures, 
loss of consciousness, and, if hypoglycemia is severe and prolonged, brain 
damage and even death. 
Physical signs that result from activation of the sympatho adrenal system 
include pallor and diaphoresis, which are often prominent, and an increased 
  
heart rate and systolic blood pressure, which are often more subtle. Evidence of 
neuroglycopenia can be the most apparent, or even the only, observable 
manifestation of hypoglycemia. Indeed, the neuroglycopenic symptoms are 
often the clues recognized by family and friends of the affected individual. 
Hypothermia is often present. Transient focal neurological deficits (e.g., 
diplopia, hemiparesis) occur occasionally. As noted earlier, permanent brain 
damage is rare. 
Hypoglycaemia is a true medical emergency which requires prompt 
recognition and treatment to prevent organ and brain damage.  The short and 
long term complications include neurologic damage, cardiovascular events and 
death. 
 
Prevention of hypoglycaemia 
The prevention of hypoglycaemia requires some principles consideration.  
These include: 
1. Diabetes self-management supported by education and empowerment. 
2. Self-monitoring of blood glucose or continuous glucose sensing. 
3. Flexible and appropriate insulin or other drug regimens. 
4. Individualised glycaemic goals. 
5. Consideration of known risk factors of hypoglycaemia. 
6. Professional support and guidance. 
  
Blood glucose monitoring is an important part of management of diabetes 
patients experiencing hypoglycaemic episodes.  Substitution of short-acting 
(regular) insulin with rapid-acting insulin (e.g. lispro or aspart) reduces 
frequency of daytime hypoglycaemia.  Substitution of long-acting (e.g., glargine 
or determir) insulin for intermediate-acting insulin (e.g., NPH or premix 70/30) 
reduces frequency of nocturnal and daytime hypoglycaemia 
Continuous subcutaneous insulin infusion with a rapid-acting insulin analog 
improves the glycaemic control and reduces the rate of hypoglycaemia 
compared with multiple daily insulin injection. 
Glycaemic goals should be individualized based on patient characteristics 
with some degree of safety.  Recognition of hypoglycaemia risk factors, blood 
glucose monitoring, selection of appropriate regimens, education programs for 
health care professionals and patients with diabetes are the major issues to 
maintain good glycaemic control, minimize the risk of hypoglycaemia, and 
prevent long-term complications. 
 
 
 
 
 
 
 
  
 
STUDY METHODOLOGY 
 
 This dissertation is based on a prospective analysis of fifty diabetic 
patients undergoing surgical procedures in Thanjavur Medical College Hospital, 
Thanjavur, from 1.1.2014  to 30.06.2014. 
 Non-diabetics, patients with major comorbid illness, patients presenting 
with postoperative infection within 36 hours of surgery were excluded from this 
study. 
 Total numbers of 50 cases were included in this study which includes 22 
females and 28 male patients.  All patients were above 30 years of age with 
mean age of study being 54 years. 
 Both patients undergoing elective and emergency surgical procedures 
were included in this study. In this study 35 patients undergoing elective 
procedures and 15 patients undergoing emergency procedures were included. 
 All patients were followed up for a period of 30 days following surgery. 
 All patients were treated with insulin to achieve glycaemic control. 
 Baseline investigations that were utilised in this study were: 
• Plasma glucose values 
o At the time of admission 
o Fasting plasma glucose value on the day of surgery 
o Postoperatively 6th hourly for first 36 hours 
  
o Patient Mean Blood glucose value of the total 7 samples 
collected as mentioned above. 
• HbA1c values 
• Total leukocyte count 
• Differential white blood cell count 
• Wound swab culture and sensitivity 
• Urine Complete examination 
• Urine culture and sensitivity 
• Sputum culture and sensitivity 
• Chest X ray 
• Blood culture and sensitivity 
Depending upon the mean plasma glucose concentration obtained as 
mentioned above patients were divided into four quartiles as follows: 
• Quartile 1 – 120 to 180 mg/dl 
• Quartile 2 – 181 to 220 mg/dl 
• Quartile 3 – 221 to 260 mg/dl 
• Quartile 4 – 261 to 350 mg/dl 
All patients were followed up for signs and symptoms of postoperative 
infections which included 
• Surgical site infections 
o Redness and pain around the wound site 
  
o Purulent discharge 
o Fever 
o Wound dehiscence 
• Pneumonia 
o Cough with expectoration 
o Fever 
o Dyspnoea 
o Newly appearing radiological changes in Chest X-ray 
• Urinary tract infections 
o Pain or burning with micturition 
o Pain in the lower abdomen or back 
o Fever 
o Cloudy or bloody urine 
o Urgency 
o Frequency 
o Urine culture with greater than 105 colonies/mL and no more 
than 2 species of organisms. 
• Sepsis 
o Fever 
o Elevated leukocyte count 
o Positive blood culture 
o Hypotension 
  
o Shock 
 
Patients who underwent the following surgical procedures were included 
in this study and were observed for signs and symptoms of postoperative 
infections as mentioned earlier. 
• Cholecystectomy 
• Appendectomy 
• Amputations 
• Intestinal resection anastomosis 
• Duodenal and gastric perforation closure  
• Hernioplasty 
• Mastectomy 
• Thyroidectomy 
• Split skin grafts 
• Trendelenberg procedure for varicose veins 
 
 
 
 
 
 
  
 
OBSERVATIONS 
 
 The following observations were made in the prospective analysis of fifty 
diabetic patients in the perioperative period.  All patients were treated with 
insulin to achieve glycaemic control.  The incidence of postoperative infections 
was evaluated in each of these patients as mentioned earlier and was grouped 
against their mean plasma glucose concentration in the perioperative period. 
 
 All the patients participated in this study were above 30 years of age. The 
minimum age is 35 years and maximum age is 75 years.  The mean age of this 
study is 54.36 years with standard deviation 11.080. 
 
Item  Min Max. Mean  S.D 
Age 
35 75 54.36 11.080 
Age Group 
 
 The number of males participated in this study were 28 and females 22.  
The sex of the patients does not have any influence on this study conducted. 
 
 
  
 
Particulars No. of respondents (n=50) 
Percentage 
(100%) 
Male 28 56.0 
Female 22 44.0 
 
 The number of patients in each quartile in this study was shown in the 
following table: 
 
Particulars No. of respondents (n=50) 
Percentage 
(100%) 
120 to 180 30 60.0 
181 to 220 11 22.0 
221 to 280 6 12.0 
281 to 350 3 6.0 
 
The postoperative infections observed in these patients were 
• Surgical Site Infections 
• Pneumonia 
• Urinary Tract Infections 
• Sepsis 
  
 
 
 Among the postoperative infections observed in the diabetic patients 
surgical site infections were the most frequent one in each quartile followed by 
pneumonia, sepsis and finally urinary tract infection  irrespective of the 
glycaemic range. 
 
 The overall incidence being as follows: 
• Surgical site infections – 46% 
• Pneumonia – 26% 
• Urinary Tract Infections – 13% 
• Sepsis – 15% 
 
 
  
 
 
 
 
 It is noted that the incidence of postoperative infections is directly 
proportional to the mean plasma glucose concentration.  The occurrence being 
less in the first quartile with glycaemic range 120 to 180 mg/dl.   
Patients in the I quartile had 16.6% incidence of surgical site infections, 
13.3% incidence of pneumonia, 6.66% incidence of urinary tract infections.  
Sepsis was observed in none of the patients with glycaemic range 120-180 
mg/dl. 
 
 
  
Quartile 2 patients whose glycaemic range was 181 to 220 mg/dl had the 
following incidence:  
• Surgical site infections – 54.5% 
• Pneumonia – 18.1% 
• Urinary Tract Infections – 9.09% 
• Sepsis – 18.1% 
 
Quartile 3 patients whose glycaemic range was between 221 and 
260mg/dl had the following incidence: 
• Surgical site infections – 66.7% 
• Pneumonia – 33.3% 
• Urinary Tract Infections – 16.6% 
• Sepsis- 33.3% 
 
The observations made in the fourth quartile patients with glycaemic 
range 261 to 350 mg/dl were as follows: 
• Surgical site infections – 100%  
• Pneumonia – 66.6% 
• Urinary Tract Infections – 33.3% 
• Sepsis – 66.6% 
 
  
 
 
 
Incidence of surgical site infections: 
 
 
 
 The incidence of surgical site infections in these patients were 
proportional to the glycaemic control achieved, the highest being in the fourth 
quartile patients i.e. 100% and the least being in the first quartile patients 
i.e.16.6%.  In the glycaemic range above 260mg/dl almost all patients had 
surgical site infections invariably stressing the importance of strict glycaemic 
control in these patients to avoid long hospital stay and the health care 
expenditure that results. 
  
 
Blood sugar Wound infection Statistical inference Negative Positive Total 
120 to 180 25(83.3%) 5(16.7%) 30(100%) 
X2=14.291df=3 
.003<0.05 
Significant 
181 to 220 5(45.5%) 6(54.5%) 11(100%) 
221 to 280 2(33.3%) 4(66.7%) 6(100%) 
281 to 350 0 3(100%) 3(100%) 
Total 32(64%) 18(36%) 50(100%) 
 
 The association of surgical site infections with blood glucose level in this 
study is statistically significant proving the need for good glycaemic control to 
prevent postoperative wound infections in these patients. 
 
INCIDENCE OF PNEUMONIA: 
 
 
 
  
 Again the incidence of pneumonia documented clinically and by newly 
occurring radiographic changes and positive sputum culture was highest in the 
fourth quartile patients with 66.6% incidence.  The incidence is lesser in the 
third quartile patients with glycaemic range 221 to 260 mg/dl with 33%.  Again 
with strict glycaemic control the incidence of pneumonia is lower in the well-
controlled group with mean plasma glucose less than 200 mg/dl; being 18.1% in 
second quartile and 13.3% in first quartile patients. 
 
Blood sugar Pneumonia  Statistical inference Negative Positive Total 
120 to 180 26(86.7%) 4(13.3%) 30(100%) 
X2=5.606 df=3 
.132>0.05 
Not significant 
181 to 220 9(81.8%) 2(18.2%) 11(100%) 
221 to 280 4(66.7%) 2(33.3%) 6(100%) 
281 to 350 1(33.3%) 2(66.7%) 3(100%) 
Total 40(8%) 10(20%) 50(100%) 
 
 
 According to the statistics, the association of incidence of pneumonia 
with increasing blood glucose level is statistically not significant in this study.  
However it is evident that the possibility of pneumonia occurrence is higher in 
the patients with high blood glucose level when compared with the well-
controlled group.   
 
 
 
  
 
Incidence of Urinary Tract Infections: 
 
 
 
 
 
 The incidence of urinary tract infections observed in each quartile (I-
6.66%, II-9.09%, III-16.6%, IV-33.3%) were similar to the observations made 
in other postoperative infections.  There is a proportionate increase in urinary 
tract infections and their complications with increasing mean plasma glucose 
concentrations. 
 
 
  
 
Blood sugar UTI Statistical inference Negative Positive Total 
120 to 180 28(93.3%) 2(6.7%) 30(100%) 
X2=2.492 df=3 
.477>0.05 
Not significant 
181 to 220 10(90.9%) 1(9.1%) 11(100%) 
221 to 280 5(83.3%) 1(16.7%) 6(100%) 
281 to 350 2(66.7%) 1(33.3%) 3(100%) 
Total 45(90%) 5(10%) 50(50%) 
 
 
 In this study, even though the rate of genito-urinary infections and its 
complications is higher in the poorly controlled group; it does not have a 
statistically significant correlation.  Despite good glycaemic control decreased 
the incidence of these complications in the postoperative period. 
  
 
 
 
 
 
 
 
 
 
 
  
 
Incidence of Sepsis 
 
 
 
 
 Sepsis was characterised by high peaks of fever, elevated leukocyte count 
and sometimes hypotension and shock.  Patients with mean plasma glucose 
concentration with 120 to 180 mg/dl did not have this potential complication in 
this study.  Patients with mean plasma glucose concentration above 180 mg/dl 
are susceptible and at higher risk with higher concentrations. The incidences in 
2nd, 3rd and 4th quartile being 18.1%, 33.3% and 66.6% respectively. 
 
 
  
 
 
Blood sugar SEPSIS Statistical inference Negative Positive Total 
120 to 180 30(100%) 0 30(100%) 
X2=15.565 df=3 
.001<0.05 
Significant 
181 to 220 9(81.8%) 2(18.2%) 11(100%) 
221 to 280 4(66.7%) 2(33.3%) 6(100%) 
281 to 350 1(33.3%) 2(66.7%) 3(100%) 
Total 44 (88%) 6(12%) 50(100%) 
 
 
 The rate of occurrence of sepsis was proportionate to the mean plasma 
glucose level, with a statistically significant relation in this study with a ‘p’ 
value of .001. 
 
 The overall incidence of postoperative infections in patients with diabetes 
undergoing surgeries is higher with greater mean plasma glucose levels.  Even 
though some infections rate does not show a statistically significant correlation 
in this study, it is evident from all of the above observations that tight 
perioperative glycaemic control within the acceptable range prevented 
unwanted postoperative infectious complications.  
 
 
 
 
  
 
 
 
 
Blood sugar Infected  Statistical inference Negative Positive Total 
120 to 180 19(63.3%) 11(36.7%) 30(100%) 
X2=9.816 df=3 
.020<0.05 
Significant 
181 to 220 3(27.3%) 8(72.7%) 11(100%) 
221 to 280 1(16.7%) 5(83.3%) 6(100%) 
281 to 350 0 3(100%) 3(100%) 
Total 23(46%) 27(54%) 50(50%) 
  
 
All of the above observations made, stressed the importance of strict 
glycaemic control in the perioperative period for an optimal recovery in the 
diabetes patients undergoing surgical procedures. 
 
 
  
 
DISCUSSION 
 
For diabetic patients, tight long-term glucose control has significantly 
reduced the incidence and severity of many chronic complications associated 
with diabetes, such as nephropathy, neuropathy, and retinopathy.  It is yet to be 
established whether long-term glycaemic control also helps to reduce 
postoperative infections and its complications, and this has been studied 
extensively worldwide.  This study therefore chose to define whether well 
controlled perioperative glycaemic status in the acceptable range is associated 
with lesser incidence of postoperative infectious complications in patients with 
diabetes undergoing various surgeries. 
 
As already mentioned, that hyperglycaemia plays an important role in the 
postoperative infectious complications.Several approaches to reduce the 
postoperative morbidity by perioperative strict glycaemic control have been 
shown to be promising in both diabetic and non-diabetic patients.  Van den 
Berghe et al demonstrated the effectiveness of strict glycaemic control, i.e. in 
the range of 80 to 110 mg/dl, against normal standard control, i.e. less than 200 
mg/dl, in critically ill patients. He also established a 42% reduction in the 
postoperative morbidity and mortality rate by strict glycaemic control. 
 
  
Several studies showed that good preoperative glycemic control is related 
with a considerably reduced postoperative infectious complication when other 
factors influencing the outcomes were adjusted.  Randomized control trials in 
medical, cardiac, and neurosurgical populations have also found reduced rates 
of bacteremia, duration of antibiotic usage, infection rates and incidence of 
recurrent infections when patients have strict glycaemic control (<150mg/dl). 
 
Bishop et al in 1992, studied the impact of HbA1c levels on postoperative 
surgical site infections in patients receiving penile prostheses prospectively.  
Infections occurred only in the diabetic patients.  Of these patients it has been 
documented about 31% were having HbA1C levels above 11.5% and only 5% 
had HbA1c levels below 11.5%.  Based on these observations, surgery was 
denied for patients with HbA1c levels above 11.5% suggesting, them to have 
poor outcomes because of  poor control of diabetic status.  This suggestion was 
widely accepted and was then “used as the ‘standard of care’ in several legal 
cases.” 
 
In 1998, Wilson et al disproved the importance of the above findings by a 
prospective study conducted in 389 patients over a period of 2 years.  The 
authors did not found a reliable association between postoperative wound 
infections and HbA1c levels more than 11.5%.    
 
  
Both of the above prospective studies relied their finding based on 
HbA1c value of 11.5% as the cut off for analysis.  Diabetes Control and 
Complications Trial group showed that an HbA1c level of 11.5% is equivalent 
to mean blood glucose of more than 310 mg/dl. Using HbA1c level of 11.5% as 
the break point places patients with 7% to 11.5% HbA1c value in the well-
controlled group which is not correct according to the current guidelines. 
 
Another study was conducted by Latham et al based on HbA1c value of 
8% as the cut-off point.  They prospectively evaluated the relationship between 
HbA1c levels and postoperative wound infections in1000 patients undergoing 
cardiac surgery.The observations made in this study were: 
• Infection rate was twice higher in the high HbA1c patients 
with values more than or equal to 8%. 
• 78% of poorly controlled patient group developed 
perioperative hyperglycaemia when compared with the well-
controlled group which is only 43%.  
• Infection rates were higher in patients with perioperative 
hyperglycaemia when compared to the euglycaemics. 
In our study the patients have been divided into four quartiles based on 
their mean perioperative plasma glucose concentration.  Patients undergoing 
various surgical procedures were included in this study.   
 
  
 
The incidence of postoperative infectious complications such as surgical 
site infections, pneumonia, urinary tract infections and sepsis were evaluated in 
the study group.  The observations made in our study shows a strong correlation 
between well-controlled glycaemic status and reduced postoperative infections 
in various surgical procedures.All patients were treated with insulin therapy 
though the type of management to achieve glycaemic control has not been 
shown significant in various studies, because it only reflects the management at 
the time of surgery and does not influence the long term glycaemic control. 
 
Better perioperative glycaemic control is associated with fewer 
complications in the postoperative period. It not only includes the postoperative 
infectious complications but also other metabolic complications associated with 
hyperglycaemia such as diabetic ketoacidosis, HHS, acute myocardial 
infarction, cerebral ischemia.  Good control of blood glucose in the 
perioperative period not only associated with better outcomes in diabetic 
patients but also in the non-diabetics.  Several prospective studies have 
established the relationship between hyperglycaemia and infections in the 
postoperative period. 
 
 
 
  
 
 As earlier discussed, hyperglycaemia impairs neutrophil activity, 
intracellular bactericidal property, chemotaxis and phagocytosis.  The degree of 
impairment correlates with the level of hyperglycaemia.  Some of these effects 
are effectively reverted with appropriate insulin therapy.  Hyperglycaemia also 
affects vascular permeability and physiological redox reactions occuring in the 
body resulting in a state of pseudo hypoxia.  This further weakens the body’s 
immune response. 
Glucose acts as a pro inflammatory mediator known to have various 
effects on immune response such as cytokine production, inhibition of 
endothelial nitric oxide.  Even in normal persons hyperglycaemia is associated 
with increased generation of reactive oxygen species.  The association of long 
term glycaemic control with reduced postoperative infections has also been 
shown because of general well-being and well controlled metabolic homeostasis 
in these patients. It is proved by the Diabetes Control and Complications 
Research Group that intensive therapy with insulin therapy has decreased the 
risk of retinopathy by 76% in type 1 diabetic patients. Intensive therapy has also 
been shown to reduce the risk of albuminuria by 56%,  micro albuminuria 
by43%, and neuropathy by 69%.  United Kingdom Prospective Diabetes Study 
Group has established similar effects in the patients with type 2 diabetes.  
Several epidemiological studies have shown decreased rate of cardiovascular 
disorders in patients with well-controlled blood glucose levels. 
  
 
Results from more recent research has triggered national associations to 
amend their guidelines to more conservative glucose parameters.  Currently, the 
Institute for Healthcare Improvement (IHI, 2011) recommends cardiovascular 
surgery patients, who are at a high risk for complications from hyperglycaemia, 
maintain blood glucose levels below 180 mg/dl for the first two postoperative 
days.  The American Diabetes Association (ADA, 2012) recommends initiating 
insulin therapy for persistent hyperglycaemia starting at a threshold of no 
greater than 180 mg/dl.  Once insulin therapy is initiated, blood glucose levels 
in critically ill patients should be maintained from 140 to 180 mg/dl.  More 
stringent goals, such as 110 to 140 mg/dl may be appropriate for selected 
patients, as long as this is achieved without significant hypoglycaemia. 
 
The ideal method of insulin administration in the perioperative period is 
by intravenous infusion.  Lazar et al compared the glycaemic control achieved 
by insulin-glucose-potassium infusion against standard intermittent 
subcutaneous insulin therapy.  Both of the regimens were started preoperatively 
and continued postoperatively for 12 hours.  The following observations were 
made in this study:  patients on insulin-glucose-potassium infusion had 
decreased incidence of postoperative infectious complications, atrial fibrillation, 
ischaemic events and better survival rates following surgery for 2 years.   
  
Studies have proven insulin infusion therapy is associated with better 
glycaemic control either with separate insulin infusion or with combined 
insulin-glucose-potassium infusion.  Separate insulin infusion has the advantage 
to adjust the rate of infusion without replacing the bag.  Even though GIK 
infusions are safe and effective, separate infusions are more preferred because 
of the possibility of easily achieving better glycaemic control. 
It is not only the extremes of glycaemia i.e. hypo or hyperglycamia that is 
detrimental, but the increased variability in the blood glucose also plays a vital 
role with respect to the postoperative outcomes and complications.  The study 
conducted by EGI and colleagues, which is a retrospective observational study, 
has established that reduced blood glucose variability is an independent factor 
affecting the outcome in critically ill patient. 
In both diabetes and non-diabetes patients postoperative hyperglycaemia 
is directly associated with a greater risk of postoperative infections in the 30day 
period following surgery leading to an extended hospital stay.  It is stated that 
for every 40 mg/dl increase in postoperative blood glucose level there has been 
a 30% increased risk for postoperative infectious complications.  A target of 
150 mg/dl of blood glucose has been recommended by the Portland Glucose 
Control Group in patients with diabetes undergoing cardiac surgery.   
 
  
Studies established decreased infectious rates in the postoperative period 
with this blood glucose target.  There is still lack of clinical studies to establish 
the effect of blood glucose control in metabolic stress induced by 
hyperglycaemia in diabetic and non-diabetic patients.  Several studies have 
prematurely stopped because of the increased incidence of hypoglycaemia and 
its complications occurring with intensive insulin therapy.   
 
 Diabetes patients undergoing surgery requires stringent glycaemic control 
with pre, intra and postoperative blood glucose monitoring.  Blood glucose level 
more than 180 mg/dl is treated with insulin therapy for perioperative glycaemic 
management. Intra operatively the ideal range to be maintained is 140 to 180 
mg/dl for safe titration of insulin therapy to avoid extremes of glycaemia and 
blood glucose variability. 
 
There are several limitations to the present study as the study was 
conducted in a single institution.  Thus the results cannot be generalised for a 
general population.  Despite adjusting several factors confounding the results, 
many risk factors associated with post-operative infections could not be 
controlled in acute settings such as nutrition, smoking etc.  In conclusion the 
relationship betweenstrict perioperative glycaemic control and a decreased risk 
of postoperative infections across a spectrum of surgical cases has been 
established. 
  
 
 If the association is confirmed in other studies, strategies to improve 
glycaemic control prior to elective surgery can be employed to decrease 
infections and improve overall outcomes for diabetic surgical patients. 
Tight glucose control in the perioperative period awaits further advances 
in real-time monitoring technology and treatment protocols but promises to 
benefit hospitalized diabetes and non-diabetes patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
CONCLUSION 
 
The following were the conclusions made from this study: 
• Patients with diabetes undergoing various surgical procedures show a 
good response in respect to glycaemic status with insulin therapy. 
• Metabolic stress induced by surgery and anaesthesia produces 
hyperglycaemia even in normo-glycaemic patients, requiring the need for 
insulin therapy in the perioperative period for optimal glycaemic control. 
• The optimal glycaemic range to be maintained for lesser postoperative 
infections is 120 to 180 mg/dl. 
• Surgical site infections are the most common postoperative infections 
occurring in diabetic patients undergoing surgery. 
• Urinary tract  infection  accounted for the least common infectious 
complication in these patients. 
• The incidence of surgical site infections and sepsis showed a statistically 
significant correlation with glycaemic status; the higher the mean plasma 
glucose level, the higher the rate of these infections. 
  
• Even though the incidence of pneumonia and urinary tract complications 
does not have statistically significant correlation, strict glycaemic control 
had lesser incidence of these infections. 
• Patients with higher blood glucose levels are at increased risk for 
postoperative infectious complications when compared with the well-
controlled diabetic patients. 
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EVALUATION OF PERIOPERATIVE GLYCEMIC CONTROL AND 
POSTOPERATIVE INFECTIONS IN PATIENTS WITH DIABETES MELLITUS 
PROFORMA 
NAME :       AGE/SEX : 
I.P. NO. :       OCCUPATION : 
ADDRESS :       UNIT  : 
DATE OF ADMISSION : 
DATE OF DISCHARGE : 
PRESENTING COMPLAINTS : 
HISTORY OF PRESENTING ILLNESS  :     
 DURATION 
 BURNING MICTURITION    YES/NO 
 FEVER  YES/NO 
 COUGH WITH EXPECTORATION   YES/NO 
 DISCHARGE FROM THE WOUND  YES/NO 
            GIDDINESS            YES/NO 
PAST HISTORY : 
 H/O DIABETES MELLITUS YES/NO 
 H/O PREVIOUS GI SURGERIES  YES/NO 
 H/O HT/BA/TB 
PERSONAL HISTORY : 
 DIET 
 SMOKING 
 ALCOHOL 
 
TREATMENT  HISTORY: 
  
             TAKING INSULIN OR ORAL HYPOGLYCEMIC AGENTS FOR DM 
 
O/E: 
GENERAL EXAMINATION : 
 ANAEMIA  +/-   FEVER  +/- 
 BP :     PULSE  : 
S/E: 
CVS : 
RS :CREPTS 
P/A : 
 WOUND INFECTION 
            WOUND GAPING 
BLOOD INVESTIGATION:   
  PREOPERATIVE BLOOD SUGAR  : 
  POSTOPERATIVELY BLOOD SUGAR EVERY 6TH HOURLY 
                                                         FOR FIRST 36 HRS  : 
  HbA1C : 
                       COMPLETE BLOOD COUNT: 
CULTURE SENSITIVITY: 
         PUS CULTURE 
         SPUTUM CULTURE 
         URINE CULTURE 
         BLOOD CULTURE 
RADIOLOGICAL INVESTIGATION: 
          X RAY CHEST  PA VIEW 
 
     
  
 
 
 
INFORMATION SHEET 
 
We are conducting a prospective study on “PERIOPERATIVE GLYCEMIC 
CONTROL AND POSTOPERATIVE INFECTIONS” in the Department 
of General Surgery , Thanjavur Medical College & Hospital, 
Thanjavur – 613004. 
 
• At the time of announcing the results and suggestions, name and identity 
of the patients will be confidential. 
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment.  
 
 
 
 
 
Signature of investigator  Signature of participant 
 
Date: 
 
 
  
 
 
CONSENT FORM 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR.S.ARAVINTH. , Post graduate in the 
Department of  General Surgery ,Thanjavur Medical College & Hospital, 
Thanjavur – 613004 and to use my personal, clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I 
also give consent for further investigations 
 
 
Place : 
Date :       Signature of participant 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Submission author:
Assignment title:
Submission title:
File name:
File size:
Page count:
Word count:
Character count:
Submission date:
Submission ID:
Digital Receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
The first page of your submissions is displayed below.
221211209.ms General Surgery ARA…
TNMGRMU EXAMINATIONS
STUDY ON PERIOPERATIVE GLYC…
INTRODUCTION.docx
670.73K
138
15,083
94,337
23-Sep-2014 11:02PM
450306755
Copyright 2014 Turnitin. All rights reserved.
  
 
 
S.NO NAME AGE SEX IP NO 
BLOOD 
SUGAR 
GROUP 
WOUND 
INFECTI
ON 
PNEUM
ONIA 
SEPSIS UTI INFECTED 
Type of 
surgery 
1 Usha 53 F 12945 2 + - - - + Eme 
2 Kumar 47 M 12623 1 - - - - - Ele 
3 Stephen 63 M 12652 1 - - - - - Ele 
4 Chinnasamy 72 M 12676 3 + + - + + Eme 
5 Rengammal 57 F 12690 1 + - - - + Ele 
6 Ahemed 64 M 12703 1 - - - - - Ele 
7 Parameshwari 60 F 12718 2 - - - - - Ele 
8 Malarkodi 58 F 12737 1 - + - - + Ele 
9 Ganesan 43 M 12744 1 - - - - - Ele 
10 Jeya 65 F 12753 3 + - - - + Eme 
11 Anjammal 49 F 12769 1 - + - - + Eme 
12 Velu 35 M 12771 1 + - - - + Ele 
13 Mala 59 F 12783 2 - + - - + Eme 
14 Seethea 56 F 12786 3 - - - - - Ele 
15 Perumal 48 M 12792 1 - - - - - Ele 
16 Kaliyamoorthy 67 M 12799 2 + - - + + Eme 
17 John 44 M 12839 1 - - - - - Ele 
18 Selvi 73 F 12845 1 - - - - - Ele 
19 Abdhul 61 M 12853 4 + + + - + Eme 
20 Chinnaiyan 45 M 12870 1 - - - - - Ele 
21 Kathan 70 M 12895 1 - - - - - Ele 
22 Amutha 45 F 12898 1 + - - - + Eme 
23 Sundaram 37 M 12917 2 - - - - - Ele 
24 Vadivelu 48 M 12920 1 - - - + + Eme 
25 Valarmathy 56 F 12948 2 + - - - + Ele 
26 Chellammal 74 F 12955 2 - + + - + Eme 
27 Nagooran 49 M 12963 1 - - - - - Ele 
28 Shanmugam 66 M 12978 3 + - + - + Eme 
29 Mookayee 62 F 12979 1 - - - - - Ele 
  
30 Guru 42 M 12986 1 - - - - - Ele 
31 Pushpam 58 F 12988 1 - - - + + Ele 
32 Chandran 42 M 12992 1 - - - - - Ele 
33 Joseph 62 M 12997 2 + - + - + Eme 
34 Mahendran 45 M 13311 1 + - - - + Ele 
35 Padmini 36 F 13327 2 + - - - + Ele 
36 Kaliyan 75 M 13346 3 + + - - + Eme 
37 Vijaya 41 F 13370 1 - + - - + Ele 
38 Kathayee 56 F 13396 4 + - - - + Ele 
39 Manikam 54 M 13402 1 - - - - - Ele 
40 Sathish 48 M 13430 1 - - - - - Ele 
41 Periyasamy 73 M 13446 1 - + - - + Ele 
42 Maniyammal 41 F 13459 3 - - + - + Ele 
43 Vaniyammal 64 F 13468 1 - - - - - Ele 
44 Muthukaruppan 58 M 13474 1 + - - - + Eme 
45 Santha 66 F 13497 2 + - - - + Ele 
46 Selvam 48 M 13519 1 - - - - - Ele 
47 Ravi 44 M 13526 2 - - - - - Ele 
48 Indirani 54 F 13547 4 + + + + + Eme 
49 Mani 38 M 13563 1 - - - - - Ele 
50 Banumathi 47 F 13599 1 - - - - - Ele 
 
  
ABBREVIATIONS 
• ACTH – Adrenocorticotrophic Hormone 
• ADA – American Diabetes Association 
• ADP – Adenosine Diphosphate 
• ATP – Adenosine Triphosphate 
• Ca++ - Calcium 
• cAMP – Cyclic Adenosine Monophosphate 
• DCCT – Diabetes Complications and Control Trial 
• DKA – Diabetic Ketoacidosis 
• DM – Diabetes Mellitus 
• FA – Fatty acid 
• FBS – Fasting Blood Glucose 
• FFA – Free Fatty Acid 
• GAD – Glutamic Acid Decarboxylase 
• GIK – Glucose-Insulin-Potassium 
• GluT – Glucose Transporter 
• GTT – Glucose Tolerance Test 
• HbA1c – GlycatedHemoglobin 
• HHS – Hyperosmolar Hyperglycaemic Syndrome 
• HLA – Human Leukocyte Antigen 
• HMG CoA – Hydroxy Methyl Glutaryl CoA 
  
• HNF – Hepatocyte Nuclear Factor 
• ICU – Intensive Care Unit 
• IDDM – Insulin Dependent Diabetes Mellitus 
• IFCC – International Federation of Clinical Chemists 
• IGT – Impaired Glucose Tolerance 
• IHI – Institute for Healthcare Improvement 
• IL – Interleukin 
• IRS – Insulin Receptor Substrates 
• KCl – Potassium Chloride 
• LADA – Latent Autoimmune Diabetes Mellitus 
• LBP – Lipopolysaccharide Binding Protein 
• LPS – Lipopolysaccharide 
• LRI – Lower Respiratory Tract Infection 
• mEq/L – milliequivalent/litre 
• mg/dl – milligram /decilitre 
• mmol/l – millimol/litre 
• MODY – Maturity Onset Diabetes of the Young 
• NADPH – Nicotinamide adenine dinucleotide phosphate 
• NGSP – National Glycohemoglobin Standardisation Program 
• NIDM – Non Insulin Diabetes Mellitus 
• NPH – Neutral Protamine Hagedorn 
  
• NPO – Nil Per Oral 
• OGTT – Oral Glucose Tolerance Test 
• PC – Pyruvate Carboxylase 
• PEPCK – Phosphoenol Pyruvate Carboxykinase 
• TAG – Triacyl Glycerol 
• TCA – Tricarboxylic Acid 
• TG – Triglycerides 
• TNF – Tumor Necrosis Factor 
• UTI – Urinary Tract Infection 
• WHO – World Health Organisation 
• ELE – Elective 
• EME - Emergency 
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